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Abstract 
Background, The renin-angiotensin system (RAS) has long been known for its 
haemodynamic regulation by means of two major angiotensin II (Ang II) receptors, 
All and AT2. A local angiotensin-generating system has been found in the exocrine 
pancreas. This study aimed, primarily, to investigate the existence of a local RAS in 
the pancreatic islets and, secondly, to elucidate its role in regulating insulin secretion 
and biosynthesis in the conditions of islet transplantation and type 2 diabetes. On 
the other hand, effects of ATi receptor blocker, losartan, on insulin release in islet 
graft and in type 2 diabetes were also investigated. 
Methods, Real-time RT-PCR and Western blot were used to investigate if RAS 
components are present in the mouse pancreatic islets, which are subject to 
regulation by islet transplantation and diabetes. The localization of AT 1-receptors in 
islets was investigated by immunocytochemistry. Batch-type incubations of isolated 
islets from normal and diabetic mice were applied for studying the influence of Ang 
II and/or losartan on the glucose-stimulated insulin release, glucose oxidation and 
(pro)insulin and total protein biosynthesis. Perfusion experiments with whole 
pancreas were utilized to assess the effect of losartan on islet graft insulin release. 
Results, Major components, namely angiotensinogen, ACE, AT广 and AT2- receptors, 
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were expressed in endogenous islets. ATi-receptors were localized to pancreatic p 
cells. Exposure of the isolated islets to Ang II induced a dose-dependent inhibition of 
glucose-stimulated insulin release and inhibited (pro)insulin biosynthesis. This 
inhibitory action was fully preventable by pretreatment of the islets with losartan, an 
AT 1-receptor antagonist. Notably, a markedly increased expression of mRNA for 
the AT 1-receptor was observed in islets retrieved from islet transplants, a finding that 
was confirmed at the protein level. Graft perfusion experiments showed a markedly 
improved first phase of insulin release to glucose stimulation in transplanted islets 
when exposed to losartan. On the other hand, mRNA for ATi, AT2 receptors and 
angiotensinogen were upregulated by type 2 diabetes in the pancreas. A decrease in 
insulin-secreting (3 cell number was found in diabetic mice islets. Losartan was 
found to increase insulin release in type 2 diabetes. 
Conclusion/interpretation. These data indicate the existence of an islet RAS. This 
system provides an inhibitory role for locally produced Ang II of glucose-stimulated 
insulin secretion, an effect mediated by the ATi receptors located on the surface of 
the islet p cells. The beneficial effect of losartan on insulin release in islet 
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Chapter 1 Introduction 
1.1 Pancreas and its functions 
1.1.1 Structure of pancreas 
The pancreas is a flat and elongated gland, analogous in its structure to the salivary 
glands, though softer and less compactly arranged than that organ (Fig. 1-1 A). It is 
long and irregularly prismatic in shape; its right extremity, being broad, is called the 
head, and is connected to the main portion of the organ, or body, by a slight 
constriction, the neck; while its left extremity gradually tapers to form the tail. The 
head is embedded in the curvature of the duodenum while the tail is tucked into the 
spleen. It is situated transversely across the posterior wall of the abdomen, at the 
back of the epigastric and left hypochondriac regions [Gray 1918]. 
The bulk of the pancreas is composed of pancreatic exocrine cells and their 
associated ducts. Pancreatic exocrine cells are arranged in grape-like clusters called 
acini (Fig. 1-IB). The exocrine cells themselves are packed with membrane-bound 
secretory granules which contain digestive enzymes that are exocytosed into the 
lumen of the acinus. From there these secretions flow into larger and larger, 
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intralobular ducts, which eventually coalesce into the main pancreatic duct which 
drains directly into the duodenum. 
Embedded within this exocrine tissue are roughly one million small clusters of cells 
called the Islets of Langerhans (Fig. 1-IB), which are the endocrine cells of the 
pancreas and secrete insulin, glucagon, somatostatin, pancreatic polypeptides and 
several other hormones. 
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Fig 1-1. Structure of pancreas 
A. Overview of the pancreas. B. Functional units of the pancreas. 
Figure is adopted from [Piano and Huether 1997] 
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1.1.2 Exocrine function 
The exocrine portion, comprising 85 % of the mass of the pancreas, is responsible for 
the secretion of fluid and various enzymes which are involved in the process of 
digestion. Pancreatic acinar cells synthesize and secrete at least 10 different 
hydrolases, including a-amylase, lipase, proteases, ribonuclease and 
deoxyribonuclease, which are the major enzymes responsible for luminal digestion of 
macronutrients. Trypsin inhibitor, a protein, is also synthesized and secreted by 
acinar cells as partial protection against early activation of trypsinogen and other 
proteases, thus preventing autodigestion. Colipase, another precursor protein, acts 
as a co-factor for lipase in fat digestion. The major dietary carbohydrate, starch, is 
hydrolyzed by the actively secreted a-amylase, and is converted into trisaccharides, 
maltose and a-limit dextrins. The pancreatic lipase breaks down the major dietary fat, 
triglyceride, into 2-monoglyceride and free fatty acids. The ribonuclease and 
deoxyribonuclease are also secreted in active forms and they are responsible for 
breaking down nucleic acids into nucleotides. Sufficiency of pancreatic exocrine 
secretion is essential for efficient digestion of food, and the subsequent normal 
absorption [Singer 1993]. 
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Secretion from the exocrine pancreas is regulated by both neural and hormonal 
controls (Chey & Chang 2001). Like the stomach, the pancreas is innervated by the 
vagus nerve, which applies a low level of stimulus to secretion in response to 
anticipation of a meal. However, the most important stimuli for pancreatic 
secretion come from three hormones secreted by the enteric endocrine system. 
Cholecystokinin (CCK) is synthesized and secreted by enteric endocrine cells (I cells) 
located in the duodenum. Its secretion is strongly stimulated by the presence of 
partially digested proteins and fats in the small intestine. As gastric chyme floods 
into the small intestine, CCK is released into blood and binds to receptors on 
pancreatic acinar cells, rendering them to secrete large quantities of digestive 
enzymes. Secretin is also a product of enteric endocrine cells located in the 
epithelium of the proximal small intestine. Secretin is secreted in response to acid 
in the duodenum when acid-laden chyme from the stomach is emptied into the 
duodenum. The predominant effect of secretin on the pancreas is to stimulate 
pancreatic duct cells to secrete water and bicarbonate for the neutralization of the pH 
of the pancreatic juice. As soon as this occurs, the enyzmes secreted by the acinar 
cells are flushed out of the pancreas through the pancreatic duct into the duodenum. 
Gastrin, with a structural similarity to CCK, is secreted in large amounts by the 
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stomach in response to food stimuli. In addition to regulating gastric acid secretion 
by the parietal cell, gastrin stimulates pancreatic acinar cells to secrete digestive 
enzymes. 
Besides the classical neuronal and hormonal controls, many regulatory factors such 
as growth factors, prostaglandin and vasoactive peptides are found to stimulate 
exocrine pancreatic secretion of bicarbonate and digestive enzymes. In this regard, 
the vasoactive peptide angiotensin II (Ang II) has been demonstrated to play a role in 
stimulating the a-amylase secretion in the pancreatic acinar cells [Tsang et a\. 2004]. 
The pancreatic endocrine hormones such as glucagon, somatostatin and pancreatic 
polypeptide are factors for inhibiting the exocrine secretion of pancreas. The vital 
role of exocrine pancreas is manifested with the fact that the insufficiency in 
pancreatic exocrine secretion as occurred in pancreatitis leads to maldigestion and 
malabsorption of our body. 
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1.1.3 Endocrine function 
1.1.3.1 Pancreatic islet and islet cells 
The endocrine pancreas represents an anatomically small part of the pancreas. It 
secretes hormones that are important regulators of energy metabolism and fuel 
homeostasis in the body. The endocrine pancreas consists of groups of cells known 
as the islets of Langerhans, which are imbedded in the exocrine portion of the gland. 
Islets comprise only about 1 % to 2 % of the total mass of the pancreas, although the 
average human pancreas has about one to two million islets. Each islet is richly 
supplied with blood vessels, and the hormones that islet cells secrete enter these 
blood vessels directly. Islets are composed of four major cell types, as listed in 
Table 1.1. In rodents, each islet is composed of 2000-4000 cells of which 60-70 % 
are P cells, 10 % are somatostatin-producing 5 cells and 20-30 % are either 
‘ 
glucagon-producing a cells or pancreatic polypeptide-producing F cells. This 
depends on whether the islets are located in the head, body or tail of the pancreas. 
Each cell type synthesizes and secretes different hormone. Glucagon and insulin, 
which are produced in the a cells and P cells, respectively, are important hormones 
involved in the regulation of blood glucose homeostasis, p cells also secrete islet 
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amyloid polypeptide (lAPP). This is a 37-amino-acid peptide originally derived 
from islet amyloid deposits in pancreas material form patients with long-standing 
non-insulin dependent diabetes or insulinomas [Karlsson et al. 1998]. Somatostatin 
produced by 5 cells regulates hormonal secretion from a and p cells. The remaining 
F cells produce pancreatic polypeptide and its roles have not yet been fully 
investigated. Each individual islet shows an orderly arrangement of the different 
cell types. Insulin secreting p cells tend to be centrally located and are generally the 
most numerous (see Table 1-1). The less numerous glucagons-secreting a cells are 
located peripherally in the islet. The 6 cells that produce somatostatin are scattered 
over between a cells and p cells. As somatostatin inhibits hormonal secretion from 
both a cells and (3 cells, this arrangement of cells may be important with regard to 
paracrine actions of somatostatin. F cells show roughly the same distribution as the 
5 cells, although they are considerably fewer in number. Islets also receive 
• • 
innervation from both the sympathetic and parasympathetic divisions of the 
autonomic nervous system. Parasympathetic stimulation usually augments islet 
hormonal secretion while sympathetic stimulation can have either a stimulatory or 
inhibitory effect, depending on whether (3-adrenergic or a-adrenergic stimulation 
dominates. 
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Table 1-1. Major cell types of the Islets of Langerhans and the hormones they 
produced. The percent of each cell type in the islets is also shown. 
Name Hormone produced % of total islet 
a cell Glucagon 25 
Insulin ^^ 
(3 cell 60 
^ Islet Amyloid Polypeptide (lAPP) 
5 cell Somatostatin 10 
F cell Pancreatic polypeptide 1 
The remaining 4% consists of connective tissue and blood vessels. 
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1.1.3.2 Regulation of insulin secretion 
Insulin, secreted by P cells, is a peptide hormone that consists of an A-chain (21 
amino acids) and a B-chain (30 amino acids) held together by two disulfide (S-S) 
bonds. It is derived from a larger precursor molecule known as proinsulin. 
Proinsulin is first synthesized in the rough endoplasmic reticulum of p cells. 
Proinsulin consists of a single peptide chain that contains both the A and B chains of 
insulin linked by a third connecting peptide segment. As the hormone is packaged 
into secretory vesicles within the (3 cells，proinsulin is converted into insulin by 
proteolytic enzymes that clip the peptide chain in two places. The peptide segment 
that is removed is known as C-peptide. When insulin is secreted into the blood, an 
equal amount of C-peptide is also secreted. C-peptide does not appear to have any 
established biological secretion. However, because it is secreted in a 1:1 molar 
ratio with insulin, it is a useful marker for insulin secretion. Most of the insulin that 
• . 
is secreted into the portal blood is removed in a first pass through the liver. In 
contrast, C-peptide is not extracted by the liver at all. As a result, whereas 
measurements of the insulin concentration in systemic blood do not quantitatively 
mimic the secretion of insulin, measurements of C-peptide do. C-peptide is 
eventually excreted in the urine. 
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In the broadest sense, insulin secretion is governed by a feedback relationship with 
exogenous nutrient supply. When substrate supply is abundant, insulin is secreted 
accordingly. Insulin then stimulates use of these incoming nutrients and 
simultaneously inhibits the mobilization of analogous endogenous substrates. 
When nutrient supply is low or absent, insulin secretion is dampened and 
mobilization of endogenous fuels is enhanced. Several factors promote insulin 
secretion, including increased blood glucose, amino acids, fatty acids, 
gastrointestinal hormones, neural and pharmacological stimuli, and other hormones 
secreted by the pancreas. Glucose is the primary stimulus of insulin secretion. 
Because insulin in turn stimulates the use of glucose, this substrate-hormone pair 
forms a feedback system for close regulation of plasma glucose levels. The 
relationship between plasma insulin and plasma glucose is sigmoidal Several other 
factors influence insulin secretion, although none is as physiologically important as 
• . 
glucose. Table 1-2 summarizes the major physiological stimulatory and inhibitory 
regulators of insulin release. When glucose is given orally, a greater insulin 
response is elicited than when plasma glucose is comparably elevated by intravenous 
administration. This augmented insulin response to oral glucose is accountable for 
by one or more intestinal hormones that are released in response to meals. They are 
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called incretins which are capable of potentiating glucose-stimulated insulin 
secretion. Glucagon-like peptide 1 and gastric inhibitory polypeptide are most 
important of these insulinogogues. This prompt gastrointestinal mechanism of 
insulinogenesis moderates the early rise in plasma glucose that follows the ingestion 
and absorption of a carbohydrate meal. Several amino acids, especially arginine, 
are known to stimulate insulin secretion. Glucose and amino acids are synergistic 
stimulators of insulin release, so that the plasma insulin rise that follows a meal 
represents more than the additive effect of its carbohydrate and protein content. In 
contrast, somatostatin released within pancreatic islets (paracrine or neurocrine) and 
from intestinal cells (endocrine) may inhibit insulin responses to meals. 
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Table 1-2. Major physiological stimulatory and inhibitory regulators of insulin 
release 
Increased by Decreased by 
D-Glucose Fasting 
Galactose Exercise 
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1.1.3.3 Mechanism for glucose-stimulated insulin release 
When plasma glucose level is increased, a specific glucose transporter (Glut-2), 
concentrated in the microvilli between jS cells, facilitates diffusion of glucose into 
the p cell. This helps maintain the glucose concentration in the |3 cell at a level that 
is essentially equal to that of the interstitial fluid. Phosphorylation of glucose by the 
enzyme glucokinase then generates an insulin-releasing signal downstream from 
glucose-6-phosphate. At the same time that glucose is being oxidized, there is a 
rapid increase in intracellular ATP concentration, i.e. ATP/ADP increase occurs in the 
P cell. An ATP-sensitive K+ channel closes, K+ efflux from the (3 cell is suppressed, 
and the cell depolarizes. Depolarization opens a voltage-regulated Ca^ channel, 
and the concentration of intracellular Ca++ rapidly increases. The elevated Ca^ 
concentration activates the mechanism for secretory granule movement along the 
» . 
microtubules. A monomeric G protein attached to the secretory vesicle interacts 
with special plasma membrane proteins (fusins). This interaction leads to the fusion 
of the granule with the membrane. Exocytosis of insulin follows. Fig. 1-2 shows 
a schematic diagram in the regulation of insulin release. 
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Fig. 1-2. Schematic diagram of regulation of insulin secretion by p cells:(l) GLUT-2 
facilitates diffusion of glucose into (3 cells. (2) Glucokinase catalyzes 
phosphorylation and raise glucose-6-phosphate levels, subsequently leads to 
increased ATP levels. (3) Increase in ATP levels closes a potassium channel and 
opens a calcium channel. (4) Potassium efflux from the (3 cells is suppressed and the 
cell depolarized. (5) Voltage dependent calcium channel opened by depolarization. (6) 
Increased calcium activated exocytosis of insulin. . ‘ .� 
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1.1.3.4 Bi-phase response of insulin secretion 
Both in vitro and in vivo, insulin secretion exhibits a biphasic response to a 
continuous glucose stimulus (Fig. 1-3). Within seconds of exposure to glucose, an 
immediate pulse of insulin is released that peaks at 1 minute and then returns toward 
baseline. After 10 minutes of continuous stimulation, a second phase of secretion 
begins. During this phase, insulin plasma levels rise more slowly and reach a 
second plateau, which can be maintained for many hours in normal individuals. 
The initial increase is due to secretion of preformed insulin, which is rapidly depleted. 
The second rise in insulin reflects a considerable amount of newly synthesized 
insulin that is released subsequently. Clearly, elevated glucose not only simulates 
insulin secretion, but also transcription of the insulin gene and translation of its 
mRNA. The biphasic response may result from (1) rapid insulin generation 
followed by the slow removal of a substance that is formed after glucose stimulation 
and acts as a feedback inhibitor of insulin release, (2) granules with different 
sensitivities to glucose, and (3) glucose stimulation of insulin synthesis that sustains 
the later secretory phase. 
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A normal biphasic response curve can be obtained by performing oral glucose 
tolerance test (OGTT) on human subjects or experimental animals. OGTT 
measures the body's ability to use glucose. To conduct an OGTT test, a person has 
to drink 75 grams of glucose after a 12-hour overnight fast. Blood samples are 
drawn at various times and the concentration of glucose is determined. It is well 
know that the administration route of glucose influences the amount of insulin 
secreted by the pancreas. If glucose is given orally, a greater increase in insulin 
secretion occurs as compared to when the same amount of glucose is given 
intravenously. This difference is due to a stimulatory effect of incretins on insulin 
secretion. Soon after food enters the Gastrointestinal (GI) tract, the blood glucose 
concentration begins to rise. 
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Fig. 1-3. Biphasic response of insulin secretion. 
Figure is adopted from [Genuth 2003] 
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1.2 Pancreatic Renin-Angiotensin system 
1.2.1 Circulating RAS and local RAS 
The renin-angiotensin system (RAS) is critically involved in the development and 
maintenance of cardiovascular and renal diseases. Such a blood-bome hormonal 
system plays an important role in the hormonal mechanisms that regulate blood 
pressure and electrolyte homeostasis [Reid et a.I 1978]. The classical circulating 
RAS cascade contains several key components, including the precursor 
angiotensinogen, two critical enzymes renin and angiotensin-converting enzyme 
(ACE), angiotensin I (Ang I), and the bioactive peptides Ang II，Ang III, Ang IV and 
Ang (1-7), as well as multiple receptor subtypes including ATia, ATib, AT2, A T 4 and 
AT7 [Gasparo et al 2000]. The major enzyme of the RAS is renin, which belongs 
to the family of aspartyl proteases and which shows a high specific affinity for its 
natural substrate, angiotensinogen. Renin is produced by the juxtaglomerular cells 
in the kidney and is secreted into the circulation. The major substrate,of renin is the 
glycoprotein, angiotensinogen. Plasma angiotensinogen is produced by the. liver. 
Renin cleaves angiotensinogen to form a decapeptide, which is called Ang I. Ang I 
is itself an inactive peptide and it is converted to Ang II by the action of endothelium 
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derived ACE. ACE is a dipeptidyl carboxypeptidase that converts angiotensin I to 
the octapeptide, called Ang II，a potent vasoconstrictor. In addition, ACE is 
responsible for the degradation of bradykinin - a potent vasodilator. In this regard, 
a c e inhibitor can lead to an accumulation of bradykinin, thus causing vasodilation 
and elevated vascular permeability. ACE is present in nearly all human tissues and 
body fluids，and is found in highest quantities in the vascular endothelium of the 
lungs and peripheral tissues. All major actions of Ang II are mediated by binding to 
receptors on the cell surface that are highly specific for Ang II. Today it is known 
that most, if not all, of the effects of Ang II are mediated via the Ang II type 1 
receptor (ATi). This receptor subtype occurs throughout the body in all species and 
it mediates most of the well-established physiological and pathophysiological actions 
of Ang II [Timmermans et al 1993]. Moreover, Ang II could be further converted 
into a number of bioactive metabolites such as Ang III and Ang IV by various 
• 鲁 
aminopeptidases. Another angiotensin metabolite, Ang 1-7 could also be generated 
upon the action of ACE-2, a homologue of ACE that exerts a cleavage of Pro-Phe 
bond from Ang I [Corvol et al 1995]. In addition to the dominant role of Ang II， 
emerging evidence has shown that Ang III，Ang IV and ang 1-7 also exhibit either 
complimentary or contrasting biological properties via the mediation of their 
20 
respective receptors [Ardaillou and Chansel 1997]. Fig. 1-3 shows a schematic 
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Fig. i_3. A schematic diagram depicting the synthesis of bioactive angiotensin 
peptides using renin, ACE and alternate enzymes. Figure is adopted from P.S. 
Leung (Current protein and peptide science, 2004). 
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It was originally thought that the RAS was an endocrine system, present only in the 
circulation. However, molecular biological research in the last decade has shown 
that, in addition to the circulating RAS system, a local RAS system exists in various 
tissues and organs. All components of the RAS system have been demonstrated at a 
cellular level in multiple tissues/organs such as adrenals [Capponi and Catt 1980], 
brain [Mendelsohn et al 1984], kidney [Okura et al 1992], pituitary [Trolliet and 
Phillips 1992], heart [Phillips et al 1993], gonads [Vinson et al 1997]，lung [Cargill 
and Lipworth 1995], epididymis [Leung et al 1999], carotid body [Lam & Leung 
2002] and pancreas [Leung et al 1999]. 
The cerebral RAS could play an important role in the regulation of cerebral blood 
flow during hypoxia in rabbit as the increase in cerebral blood flow was attenuated 
by RAS inhibitors [Mazen et al 1995]. The adrenal RAS has been reported to 
regulate the tissue growth and functions of glomerulosa in rat [Vinson 1995]. 
• , 
Besides, the cardiac RAS has been shown to play a regulatory role in cardiac 
hypertrophy and remodeling [Dostal 2000] as well as in the pathogenesis of 
atherosclerosis [Shieffer et al 2000]. In the epididymis, locally generated Ang II 
plays a paracrine/autocrine pathway in regulating anion and fluid secretion by the 
epididymis [Leung and Semia 2003]. In the carotid body, the functional expression 
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of ATi receptor in the type-I cells of rat carotid body has been demonstrated [Fung et 
al. 2001]. Ang II in carotid body can mediate the intracellular calcium release and 
thus regulating the neural activity of the carotid body chemoreceptors [Leung et al. 
2003]: A large body of work has substantiated that the locally generated Ang II 
may have significant proinflammatory actions, such as the production of reactive 
oxygen species, inflammatory cytokines, chemokines, and the modulating abilities in 
cell growth and injury of the end-tissue. In this regards, Ang II was reported to be 
responsible for the hepatic fibrogenesis [Paizis et al 2001]. In addition, the 
pulmonary Ang II has been demonstrated to act as a potential profibrotic mediator in 
the lung via the activation ofATi receptor [Marshall et al. 2000]. 
Activation of the RAS produces short-term and long-term effects. The short-term 
effects (sodium and water retention, vasoconstriction, and positive inotropic effects 
on the heart) are probably produced by the circulating RAS system. In contrast, 
• . 
activation of the tissue RAS is likely to result in long-term effects such as 
hypertrophy of the heart and blood vessels [Ferario 1990]. To this end, a fuller 
understanding of local RAS could give rise to important clinical implications for a 
number of diseases. 
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1.2.2 RAS inhibitors 
1.2.2.1 Angiotensin converting enzyme inhibitor 
The fact that angiotensins contribute to the pathogenesis of several diseases 
stimulated the development of drugs that inhibit the RAS. This has been an 
exciting and fruitful area of research, particularly during the past decade, in which 
potent and specific inhibitors on the formation or actions of Ang II have been 
developed (Fig. 1-4). 
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Figure 1-4 Schematic presentation of the RAS cascade with its relationship to ACE 
inhibitor and Ang II receptor antagonists. , 
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As renin catalyzes the first and rate-limiting step of the system and has high 
specificity for angiotensinogen, blockade of the production of Ang II by direct 
inhibition of renin has long been a therapeutic goal. Indeed, intravenous 
administration of the early renin inhibitors, such as enalkiren and remikiren, did 
reduce angiotensin levels and lower blood pressure without any important adverse 
effects [Weber et al 1990; Neutel et al 1991; van den Meiracker et al. 1993; Kobrin 
et al 1993]. However, due to relatively low potency, poor oral bioavailability, short 
durations of action and high costs of synthesis, none of these peptide inhibitors has 
made it to the end of clinical trials [Fisher and Hollenberg 2001]. Nowadays, a new 
class of completely nonpeptide, orally active renin inhibitors such as aliskiren, has 
been shown to inhibit the production of Ang I and II and to reduce blood pressure in 
sodium-depleted marmosets [Stanton et al 2003]. 
The other two most widely used RAS inhibitors are ACE inhibitor and Ang II 
receptor antagonists. ACE is a key enzyme in the RAS for the conversion of the 
bioinactive Ang I into the effector peptide Ang II. The first ACE inhibitor Captopril 
was created in 1975 with the application of structure-based drug design technology 
[Pfeffer et al 1988]. The available ACE inhibitors can be divided into 3 groups: the 
sulphydryl-containing group such as captopril, the carboxyl-containing group such as 
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enalapril and ramipril, and the phosphorous-containing group such as fosinopril 
[Wyvratt 1988; Voors et al. 1995]. Generally, ACE inhibitors belonging to the 
carboxyl group are more potent than captopril but carrying lower bioavaliabilities 
while the phosphorous-containing group has longer duration of effectiveness. They 
both reduce the formation of Ang II by blockade of ACE. 
1.2.2.2 Non-specific Ang II receptor blocker 
Since Ang II is the key active peptide of the RAS, Ang II receptor blockers are 
thought to be more effective than the action of ACE inhibitor. It blocks the RAS 
pathway more specifically at the last step, without worrying about the accumulation 
of bradykinin and the ACE-independent formation of Ang II. Saralasin, which is a 
peptide-based analog of Ang II, acts as an antagonist for Ang II by competitively 
blocking both the ATi and AT2 receptors. Saralasin was found effective in treating 
hypertension in patients with high renin concentration, but not in patients with low 
plasma level of renin [Satia et al. 1995]. Given that ATi and AT2 receptors may 
counteract to each other, the blockade of RAS by saralasin could only represent the 
compensated results of the two receptor subtypes. In view of this, selective 
receptors for AT 1 and AT2 became more noteworthy. 
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1.2.2.3 Specific ATi receptor antagonist 
The ATi receptor belongs to the seven transmembrane class of G-protein coupled 
receptor and is encoded by a 359-amino acid protein. Two isoforms, ATia and AT比 
have been identified in rodents [de Gasparo et al. 2002]. The specific ATi receptor 
antagonist interacts with amino acids in the transmembrane region of the ATi 
receptor and occupies space among the seven helixes, thus preventing the binding of 
Ang II. Losartan (Dupont pharmaceuticals, Dup 753; Merck and Co., MK954) is 
the first marketable non-peptide ATi receptor antagonist [Timmermans et a\. 1993]. 
It overcomes the drawbacks of saralasin, with higher bioavailability, selective 
antagonism to ATi receptor without exhibiting agonist effect in the course of the 
RAS blockade. The ATi receptor antagonist was approved by FDA in 1995 for the 
treatment of hypertension, either alone or in combination with other antihypertensive 
agents. Other specific ATi receptors including candesartan cilexetil, irebesartan and 
• , 
valsartan are biphenyl analogs of losartan. These antagonists for ATi receptors have 
different oral bioavailabilities, protein binding properties and acting duration time. 
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1.2.2.4 Specific AT2 receptor antagonist 
The binding activity of Ang II with AT2 receptor is similar to that of ATi receptor. 
The AT2 receptor also possesses a seven transmembrane domain but is encoded by a 
363-amino acid protein [de Gasparo et al 1995]. A series of 
1,2,3,4-tetrahydrosioquinoline-3-carboxylic acids including EXP655 , EXP801， 
PD121981, PD123317 and PD123319 have been developed with high binding 
affinities selectively to AT2 receptor for Ang II. PD123319 is the most commonly 
used non-peptide AT2 receptor antagonist. 
1.2.3 RAS in the pancreas 
1.2.3.1 Expression and localization of pancreatic RAS 
In recent years, the existence of a local angiotensin-generating system in the pancreas 
• . 
of various species was shown. The expression of the bioactive peptides Ang II, Ang 
III and Ang (1-7)，the precursor angiotensinogen, as well as the ATi and AT2 receptor 
subtypes were first demonstrated within the dog pancreas [Chappel et al 1991; .1992]. 
Subsequent studies demonstrated the presence of key RAS components in rat [Ghiani 
and Masinin 1995; Leung et al 1999]，mouse [Leung at al 1998] and human 
30 
[Tahmasebi et al. 1999]. In terms of the acinar cells in pancreas, mRNA expression 
of all components of the RAS including AT2, ATia and ATib subtypes, as well as renin, 
angiotensinogen and ACE were demonstrated in the AR42J cell line [Chappell et al 
2001]. With autoradiography, Ang II receptors were shown to be distributed 
throughout the pancreas, but with the highest density on acinar cells. In rat 
pancreas, Ang II receptors are mainly located in islets, and preferentially to the 
surface of a and 5 cells [Ghiani and Masini 1995]. The majority of binding sites in 
the canine pancreas are AT2 receptors, although ATi receptors can also be found 
[Chappell et al. 1992]. In rodents ATi and AT2 receptors were specifically localized 
to various elements of the pancreas [Leung et al. 1997]. Major RAS components at 
gene and protein levels were unequivocally expressed in the rat pancreas [Leung et al. 
1999]. In the human pancreas, the presence of both ATi receptors and renin have 
been demonstrated in islets [Tahmasebi et al 1999]. All these results substantiate . 
• • 
the existence of a pancreatic RAS, which have important roles in the regulation of 
pancreatic exocrine and endocrine functions [Leung and Carlsson 2001]. 
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1.2.3.2 Regulation of pancreatic RAS and its clinical relevance 
The pancreatic RAS is subjected to various physiological and pathophysiological 
regulations. In terms of endocrine pancreas, the local RAS was subjected to 
regulation in pancreatic endocrine tumours, suggesting that alterations in the RAS 
may have pathophysiological relevance in patients with islet tumours such as 
pancreatic endocrine turners (PET). In that study, the gene expressions of AT2 
receptor and angiotensinogen were significantly increased whereas the mRNA for 
ATi receptor was decreased in human PET samples [Lam and Leung 2002]. Studies 
with ACE inhibitor also showed that the pancreatic RAS may play a pivotal role in 
regulating islet blood perfusion, thereby affecting insulin release by the islet cells 
[Carlsson et al. 1998]. In this study, a specific ACE inhibitor enalaprilat and the 
Ang II antagonist Saralasin were administered to the isolated perfused rat pancreas. 
Interestingly, an increase in whole pancreatic blood flow, notably the 
• . 
microcirculation of islet blood flow, was noted； Addition of Ang II induced a 
marked vasoconstriction, which could delay the first phase of insulin release in 
response to glucose. Furthermore, a sustained decrease in tissue oxygen tension 
was detected in pancreatic islet transplants [Carlsson et al 1998] while chronic 
hypoxia upregulated the pancreatic RAS components [Chan et al 2000] and 
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enhanced the oxidative stress in the pancreas [Ip et al. 2002]. In this condition, an 
increased sensitivity to RAS components by chronic hypoxia should be deleterious 
for islet graft function. This might be due to a reduction in blood perfusion of islet 
transplants and/or an enhanced production of reactive oxygen species (ROS) in islet 
transplants. Other studies has also shown that cerulein-induced acute pancreatitis 
could upregulate the local pancreatic RAS [Leung et al 2000]. Administration of 
Saralasin attenuated the oxidative stress and tissue injury following cerulein-induced 
pancreatitis [Ip et al. 2003]. These data suggest that an activation of pancreatic 
RAS such as in acute pancreatitis or in islet transplant appears to be closely 
associated with the generation of oxidative stress within the pancreas, which in turn 
may lead to disturbances in pancreatic functions. Emerging data also shown that 
patients treated with the ACE inhibitors due to a high risk of cardiovascular events, 
result in a marked reduction in the incidence of diabetes and development of diabetes 
complications [Yusuf et al 2000]. Taken together, the potential influence of 
pancreatic RAS exert on cellular growth in exocrine acinar cells and on the 
generation of free radicals in islet transplantation and other clinical conditions； The 
significance of a local pancreatic RAS could provide an insight into several exocrine 
and endocrine pancreatic diseases, such as pancreatitis, pancreatic cancer, islet 
transplant failure and diabetes mellitus [Leung 2003]. 
1.3 Islet Transplantation and RAS 
1.3.1 Whole pancreas and islet transplantation 
For decades, researchers have searched for ways to restore blood sugar control 
through transplanting pieces or extracts of pancreas in patients with diabetes. Apart 
from the daily need for multiple insulin injections and blood glucose monitoring, 
patients with type 1 diabetes mellitus (TIDM) are at greater risk for end organ 
complications, cardiovascular disease, and premature mortality. Treatment aimed at 
keeping the blood sugar, blood pressure, and blood lipids within their normal ranges 
has been shown to markedly reduce diabetes complications [Gaede et al. 2003]. 
However, few treatments have achieved these goals for long term. The main 
• . 
reasons for transplantation therapies are thus to overcome the lifelong need for daily 
insulin injections and frequent blood glucose testing, to promote maintenance of near 
normal blood glucose levels, and to avoid or even reverse the long-term diabetes 
associated complications. 
The first known transplantation report was in 1895, in which minced sheep's 
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pancreas and extracts of pancreas were used for oral and subcutaneous therapy 
[Williams 1894]. This report turned out to be a failure in the lack of 
immunosuppression. No successful case was reported until 1972，when islet 
isografts from normal rats were used to reverse streptozotocin-induced diabetes in 
rats [Ballinger and Lacy 1972]. After that, successful islet autograft transplantation 
was reported in humans [Largiader et al. 1980]. In this autograft transplantation, 
the removed pancreas was minced, digested with collagenase, and centrifuged to 
separate islets from exocrine cells and infused the islets into the patient's liver 
through the portal venous circulation. Since the "Edmonton protocol" was 
published [Shapiro et al. 2000], researchers at the University of Alberta in Edmonton, 
Canada, have continued to use this new procedure to transplant pancreatic islets into 
patients with TIDM. The "Edmonton protocol" is a method using larger quantity of 
islets and a combination of drugs such as sirolimus, tacrolimus and daclizumab, 
which were less toxic to suppress the immune system. The largest and most recent 
report on the clinical outcomes of the Edmonton experience was published in 2002 
[Ryan et al. 2002]. The authors reported 54 islet infusions in 30 recipients with 
type 1 diabetes and provided detailed follow-up data on 17 consecutive patients, all 
of whom became insulin-independent. These reports confirmed that pancreatic 
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islets, isolated from brain-dead donor pancreata and infused into a recipient's portal 
vein, can secrete insulin in a manner sufficient to regulate the blood sugar. 
The goal of pancreas or islet transplantation is to achieve glycemic control with 
minimal risks. The significant risks associated with whole organ transplantation 
usually limit its use to co-transplantation with other organs. Pancreas 
transplantation is still associated with significant morbidity in terms of surgical risk 
and of cost. Islet transplantation, a much less invasive procedure than 
whole-pancreas transplantation, offers the hope to cure diabetes [Ryan et al 2001]. 
1.3.2 Problems encountered in islet transplantation 
Although islet transplantation can lead to insulin independency in patients with 
TIDM, the long-term outcome so far is disappointing. One of the major obstacles 
is the limited availability of human islet tissue. In the United States, there are 
approximately 1 million patients with TIDM and 16 million with type 2 diabetes 
who may wait for islet transplantation. However, only about 6000 human' brain 
dead donors are suitable for organ donation each year [United Network for Organ 
Sharing 2002]. Despite all the limitations associated with whole pancreas 
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transplantation, there are still about 80 % of the best donors used for whole pancreas 
transplantation. Furthermore, even the most experienced islet isolation center can 
only have 50 % chance to isolate islets with good quality and quantity. Taken these 
into consideration, if one recognizes that almost all islet recipients currently require 
islets from 2-4 donors, only less than 1000 recipients per year (out of the 17 million 
in need) could benefit from an islet transplant. Clearly, a replenishable cellular 
source of physiologically regulated insulin secretion will be required. 
On the other hand, rejection is another problem with islet transplantation. The 
immune system is programmed to destroy bacteria, viruses, and tissue it recognizes 
as "foreign," including transplanted islets. Immunosuppressive drugs are needed to 
keep the transplanted islets functioning. These drugs are often associated with 
serious side effects. Therefore, patients also contend with a higher risk for 
infections resulting from a weakened immune system. To solve this problem, some 
researchers are attempting to encapsulate either allogeneic or xenogeneic islets 
behind a barrier that allows glucose to enter the islet P cells and secrete insulin 
without immune detection and immune mediated destruction [Dickson et a//2003; 
Kobayashi et al 2003]. 
In addition to the above two major hurdles for islet transplantation, there are many 
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more barriers to be overcome, such as imperfect glycaemia control, unknown 
durability of transplanted islet function, unknown safety of intraportal islets, 
unknown long-term effects on secondary complications and last but not least, 
difficulties in identifying the ideal islet or pancreas candidate. 
1.3.3 Potential role of RAS in islet transplantation 
The reason for the need of large amount of islets is poor or inadequate engraftment of 
the islets in the implantation organ. Normally, pancreatic islets have a rich blood 
supply which is of crucial importance for the delivery of oxygen and nutrients to the 
islet cells and for the dispersal of the secreted hormones to their target organs 
[Jansson 1994]. However, the islet vasculture disrupts when they are isolated and 
cultured before transplantation [Parr et al 1980]. Thus after transplantation, the 
islets are solely by diffusion from blood vessels in the surrounding tissues [Davalli et 
a l 1996]. Furthermore, a markedly decreased oxygen tension in islets transplanted 
1 month post-transplantation was observed [Carlsson et <3/. 1998] and the newly 
formed blood vessels were immature [Lukinius et al. 1995]. Clearly, attempts to 
improve islet revascularization are urgently needed to decrease the number of 
transplanted islets to obtain insulin independence. The pancreatic RAS is shown to 
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be responsive to a number of physiological and pathophysiological stimuli, such as 
chronically hypoxic condition and during other clinical conditions, e.g. acute 
pancreatitis [Leung and Carlsson 2001]. It was shown that infusion of Ang II 
induced a dose-dependent reduction in both whole pancreatic and islet blood flow, 
which was most pronounced in the former. Administration of enalaprilate, an 
inhibitor of angiotensin-converting enzyme, and saralasin, a nonselective Ang II 
receptor antagonist, preferentially increased islet blood flow [Calrlsson et al 1998]. 
From these results, it could be speculated that increased local levels of RAS 
components in islet grafts may also occur to support islet revascularization and to 
decrease oxygenation between islets in the graft. The significance of local RAS in 
the pancreas and its regulation by inflammation and low oxygen tension conditions 
could be of potential importance in the study of islet transplantation. The target for 
the inhibition of pancreatic or islet RAS by virtue of using specific RAS inhibitors 
‘ • 
could also provide an insight into islet transplantation. 
. � 
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1.4 Diabetes Mellitus and RAS 
1.4.1 Diabetes Mellitus 
Diabetes mellitus is a group of metabolic disorders with one common manifestation: 
hyperglycemia caused by insulin deficiency. Diabetes mellitus is by far the most 
common endocrine disorder and is a worldwide health problem. Diabetes is the 
third leading medical cause of death and the second leading cause of blindness in the 
United States. This disease is not a single disease as was once thought. Instead, it 
is now well known that diabetes comprises a heterogeneous group of disorders that 
differ in both cause and severity. Several immediate complications can arise if the 
glucose concentration in the blood is not checked by insulin. These problems 
include hyperglycemia, ketoacidosis and electrolyte imbalance. When 
hyperglycemia becomes severe, the concentration of glucose in the blood can exceed 
the capacity of the kidneys to recapture glucose by active transport; glucose will be 
excreted in the urine, thus resulting in glucosuria. Without insulin, the unopposed 
actions of glucagon result in increased ketone formation by the liver. , The primary 
ketones are organic acids, i.e. acetoacetate, p-hydorxybutyrate and acetone. When 
they are produced in sufficiently large amounts, the normal acid/base balance in the 
body is considerably disturbed, resulting in the condition termed ketoacidosis. 
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Ketones also carry cations, such as sodium and potassium into the urine, and thus 
concomitant with severe ketoacidosis is a loss of these ions. This results in an 
electrolyte imbalance in the body. If left untreated, severe ketoacidosis 
accompanied by dehydration can rapidly lead to coma and death. In addition to 
acute complications, long-term complications of diabetes may occur. These 
secondary complications often involve gradual changes that develop over a period of 
years and may shorten the life expectancy of the patients. The most common 
secondary complications are seen within the vascular system, such as narrowing of 
larger blood vessels in the brain, heart, and lower extremities. The resulting 
reduction in circulation to these areas may result in stroke, heart attack, or loss of 
limb. Lesions in the retina of the eye can result in eye disease termed diabetic 
retinopathy. Another common secondary complication involves impairment in 
nerve function termed diabetic neuropathy, resulting in abnormalities in bladder or 
gastrointestinal function. 
Diabetes mellitus is classified into two types based on clinical symptoms and specific 
etiologic characterization. 
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1.4.2 Type 1 diabetes and its animal models 
TIDM (also known as insulin-dependent diabetes; 5 % to 10 % of all cases) is 
associated with a specific and complete loss of pancreatic |3 cells, leaving islets 
composed of an increased number of a, 5 and F cells. Thus, TIDM can be thought 
of as a specific p-cytectomy, a phenomenon mimicked in animals with the use of 
chemical agents like alloxan or streptozotocin (STZ). Autoimmune destruction of 
pancreatic P cells has been suggested to be the most common cause of TIDM. 
Other initiating factors include virus and chemical toxins. Less common causes of 
TIDM are conditions that result in a reduction in the mass of islet cell tissue, as 
observed in several types of pancreatitis, pancreatic carcinoma, and pancreatectomy. 
Exogenous insulin is required to reverse the high glucose state. Patients with 
TIDM must receive daily insulin injections. 
Animal models featuring physiological and pathological changes characteristic of 
each diabetes subtype are important to understand this complex disease better and to 
propose potential treatments. Specific etiological factors and/or genetic 
backgrounds can be selected and combined to produce a particular type of 
experimental diabetes. This allows the researcher to explore particular biochemical 
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or anatomical alterations and thus to study disturbances found in human diabetes. 
Chemically induced TIDM is the most commonly used animal model of diabetes. 
The chemical agents used specifically damage (3 cells, cause temporary inhibition of 
insulin production, and diminish the metabolic efficacy of insulin in target tissues. 
In general, chemicals that damage P cells are of specific interest as they closely 
reproduce lesions that occur during (3 cell destruction in TIDM. Moreover, these 
agents provide relatively permanent diabetes that is suitable for long-term studies. 
Alloxan, a cyclic urea analog was the first agent in this category to produce 
permanent diabetes in laboratory animals [Dunn et al 1943]. STZ has replaced 
alloxan later as the principal agent due to the greater selectivity of p cells and the 
lower mortality rate seen in STZ diabetic animals [Rakieten et al. 1963]. Genetic 
models of TIDM include the NOD mouse and the BB diabetic rat. In these animals, 
diabetes occurs spontaneously with a total dependence on exogenous insulin for 
survival. ‘ 
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1.4.3 Type 2 diabetes and its animal models 
Type 2 diabetes (T2DM，also know as non-insulin-dependent diabetes; represent 90 
to 95 % of the diabetic population). T2DM is due to pancreatic p cell dysfunction 
and/or insulin resistance. Normal or often higher-than-normal concentrations of 
insulin may be present in the blood, but cells of target tissues such as adipose and 
muscle simply do not respond to the hormone as they normally would, resulting in a 
condition called insulin resistance. Nearly 90 % of the patients with T2DM are also 
obese. The exact relationship between the obesity and insulin resistance is not clear, 
but the severity of the disease can often be reduced considerably if the patients are 
placed on a diet and lose weight. In addition to diet, persons with T2DM are often 
treated with oral hypoglycemic agents known as sulfonylureas, which stimulate 
insulin secretion from (3 cells. Sulfonylureas also appear to augment the actions of 
insulin in tissues and therefore help overcome the insulin resistance in target tissues. 
Current research strongly suggests that this disease arises as a consequence of failure 
of insulin action due to abnormalities at the cell surface or within the cell, deficiency 
in insulin secretion or a combination of these processes. 
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The genetic T2DM models are produced though selective breeding, spontaneous 
mutations or genetic engineering. One example is the db/db mouse, in which 
diabetes mutation is a result of a point mutation in the diabetic gene, db, which 
encodes a leptin receptor, Lepr [Chen et al 1996]. Other genetic models include 
ob/ob mouse, KK mouse, NZO mouse, fa/fa Zucker rat and fa/fa diabetic Zucker rat. 
Most of these models demonstrate various degrees of glycemia, insulinemia and 
obesity. Chemically induced T2DM is obtained through injection of agents that 
produce the desired pathology. The most commonly used is STZ. A mild and 
stable form of diabetes, resembling type 2 human diabetes, is produced by a single 
dose of STZ (90 mg/kg i.v.) in neonatal rats [Bonneve et al 1981]. The induced P 
cell injury is followed by limited regeneration, primarily as a result of ductal budding 
rather than mitosis of pre-existing P cell, creating a short-term normalization of 
glycemia. At 6 to 15 weeks of age, the rats have an impaired glucose disposal rate 
and significant P cell secretory dysfunction. Surgical T2DM can also be produced 
by removal of various amounts of pancreatic mass. ‘ 
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1.4.4 RAS blockade in diabetes patients 
Diabetes is a common cause of end-stage renal disease and cardiovascular disease, 
both of which are major public health issues. One of the mechanisms of blood 
pressure elevation in renal disease is overactivity of the RAS. ACE inhibitors such 
as ramipril and captopril prevent the formation of Ang II, a molecule that raises 
blood pressure by vasoconstriction of arterial vessels. A newer class of drugs to 
treat hypertension is the Ang II receptor blockers (ARBs). These agents, such as 
irbesartan and losartan, work by inducing blockade of Ang II binding to its ATi 
receptors. Several studies have demonstrated the benefits of RAS blockade in 
reducing blood pressure and cardiovascular and renal risk. More recent clinical 
trials suggested that blockade of the RAS, either by inhibiting the ACE [Hansson et 
al 1999] or by blocking the ATi receptor [Dahlof et al. 2002], can reduce 
cardiovascular and renal functions independently of their antihypertensive effects. 
In the Captopril Primary Prevention Project (CAPPP) trial, incidence of diabetes was 
14 % lower in the captopril group than in the conventional group [Hansson et al. 
1999], whereas, in the Heart Outcomes Prevention Evaluation (HOPE) trial, there 
was 34 o/o reduction in relative risk for the development of type 2 diabetes [Yusuf et 
al 2001]. Similarly, in the Losartan Intervention For Endpoint Reduction in 
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Hypertension study (LIFE), the incidence of type 2 diabetes was reduced by 25 % in 
the losartan group [Dahlof et al 2002]. Furthermore, the RAS blockade has also 
been shown to reduce the risk of renal disease in diabetes. A previous study 
involving patients with type 1 diabetes showed that captopril, an ACE inhibitor, 
could reduce the risk of renal disease progression by 50 %. New trials with the Ang 
II receptor blockers examining the potential benefits of these newer agents in type 2 
diabetic patients were initiated on the basis of the results of the captopril study. 
[Lewis et al 1993]. 
1.4.5 Potential role of RAS in diabetes mellitus 
Several regulatory systems control the islet function and (3 cell mass by means of 
neural, hormonal, and paracrine/autocrine/intracrine pathways. Of great interest in 
this context might be some paracrine/autocrine regulators such as angiotensins. 
Recent evidence exists for the presence of a local RAS in the pancreas, which is 
subject to activation by various conditions. Such a local islet RAS, if activated,-
could result not only in the reduction of islet blood flow, but also in the direct 
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inhibition of islet insulin secretion and in a subsequent deterioration of the (3 cell 
mass. 
Concerning type 1 diabetes, profound effects of Ang II on blood flow and insulin 
release in transplanted islet has been observed [Olsson et al. 2000]. It may be 
speculated that hyperactivity of the RAS in islet vasculature impairs insulin release. 
Indeed, in the diabetic state, increased ACE concentrations occur in the mesenteric 
vasculature, at least in animals [Jandeleit et al 1992]. An increased vasopressor 
responsiveness to Ang II in diabetic patients has also been observed [Christlieb et al 
1976; Drury et al 1984]. 
Even though ACE-inhibition has shown beneficial effects on islet function in several 
clinical studies, whether this improved insulin secretion response reflects vascular 
effects in the islets, or is mediated via Ang II receptors on (3 cells remains to be. 
* . 
elucidated. The involvement of the islet RAS for the close correlation that exists 
between hypertension and type 2 diabetes in the clinical trials, emerges as a potential 
link between RAS and pancreatic islet functions. This also provides a potential 
mechanism for the observed beneficial effects of RAS inhibition in reducing the 
diabetes incidence in at-risk patients with hypertension in large clinical trials. In 
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the future, it will therefore be important to investigate more closely the role of the 
islet RAS in human diabetes, especially with regard to effects on P cells and insulin 
secretion. 
1.5 Aims of study 
Based on the available information described in the introduction, the present study is, 
specifically, designed to investigate the existence of a islet RAS in the pancreas: its 
role in insulin secretion, in islet transplantation and in diabetes. Specifically, the 
aims of present study are set as follows: 
• Existence of a local RAS in pancreatic islets 
參 Role of islet RAS in insulin secretion 
參 Regulation of islet RAS by islet transplantation 
參 Role of islet RAS in insulin secretion in T2DM 
• Regulation of islet RAS by T2DM 
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Chapter 2 Materials and Methods 
2.1 Experimental animals and mouse models 
2.1.1 Experimental animals for islet isolation and transplantation 
Male C57BL/6J mice aged 8-10 weeks were used in all experiments. The animals 
were bred in the Laboratory Animal Services Center of the Chinese University of 
Hong Kong, fed with standard rat chow, and supplied with water ad libitum. The 
mice were housed under a 12-hour light/dark cycle with constant ambient 
temperature of 22 °C ± 1 °C and relative humidity in the range of 60 % to 80 %. The 
experimental procedures were approved by the Animal Experimentation Ethics 
Committee of the Chinese University of Hong Kong and followed the "Principles of 
laboratory animal care" (NIH publication no. 85-23, revised 1985). The animals 
were subjected to pentobarbital-anesthetic management when needed during the 
whole period of experiment and were killed by cardiac excision. 
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2.1.2 Mouse model for type 2 diabetes 
6-8 weeks genetically diabetic C57BL/KsJ+db/+db mice and their age matched 
nondiabetic littermates C57BL/Ksjm+/+db are used in experiments for the regulation 
of pancreatic islet RAS in type 2 diabetes. 
The C57BL/KsJ+db/+db mice (common name db/db mice) has a point mutation in 
the diabetic gene, db, which encodes a leptin receptor, Lepr [Chen et al 1996]. 
Leptin is a recently isolated hormone produced by adipocytes and is a powerful 
regulator of satiety centers in the brain. A defect in either leptin production or 
transmission of the leptin signal in db/db mice, respectively, results in a syndrome of 
obesity and diabetes which closely resembles that which occurs in humans. Leptin 
release is regulated in part by nutritional status and its expression in adipose tissue is 
up-regulated by insulin. The control animals are nondiabetic heterozygous 
C57BL/Ksj-m+/+db mice (common name m+/+db mice). 
The animals were bred in the Laboratory Animal Services Centre of the Chinese 
University of Hong Kong and housed as the same condition as that mentioned in the 
last section. 
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2.2 Islet isolation and transplantation 
2.2.1 Enzymatic islet isolation 
Islets were isolated from the pancreas as described previously [Andersson 1978]. 
Briefly, male C57BL/6J mice aged 10 weeks were killed by cervical dislocation and 
the pancreata were dissected out. The pancreata were then placed in cold Hanks' 
solution (Sigma Aldrich, St. Louis, USA) and injected with Hanks' solution by 
means of a 27 G syringe. The inflated pancreata were cut into small pieces with 
similar size. These pieces were transferred to vials containing collagenase solution 
(25 mg/8ml Hanks) (Roche Molecular Biochemicals, Mannheim, Germany). The 
vials were shaken vigorously at 3 7 � C for approximately 15 minutes. The 
collagenase digestion was terminated by the addition of cold Hanks' solution and the 
digest was then washed three times by filling the vial with Hanks. The islets were 
then picked using mouth-pipettes and cultured free-floating for 4-7 days in 
non-adherent culture dishes using RPMI 1640 medium (Sigma Aldrich, St Louis, 
USA) supplemented with 10 % (vol/vol) fetal bovine serum (Sigma Aldrich). 
Medium was changed every other day. 
52 
2.2.2 Islet transplantation 
The method for islet transplantation has been described previously [Carlsson et al 
1998]. Briefly, 300 isolated islets were packed into the tip of the mouth-pipette 
after 4-7 days of culture. A recipient C57BL/6J mouse was anesthetized with an i.p. 
injection of 2.5 % (wt/vol) pentobarbital and a small incision was made on the left 
renal capsule. The tip of the mouth-pipette was introduced between the renal 
parenchyma and the capsule followed by gentle ejection of the pellet. Four weeks 
after transplantation, the mice were killed and the islet transplant was dissected out. 
As control, pancreatic islets isolated from age-matched animals were used. 
2.3 Biological assay on islet functions 
2.3.1 Measurement of islet insulin release 
• , 
Measurement of islet insulin release was carried out following the procedure as 
described previously [Wang and Gleichmann 1998]. Groups of ten islets were 
transferred in duplicate to Falcon 24-well culture plates containing 0.25ml 
Krebs-Ringer bicarbonate buffer (KRBB) supplemented with lOmmol/1 HEPES and 
2 mg/ml of bovine serum albumin (BSA). For the first hour of incubation at 37 °C 
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( O 2 / C O 2 , 95:5), the medium contained 1.7 mmol/l glucose. The medium was then 
removed and replaced with 0.25 ml of KRBB containing 16.7 mmol/l glucose and 
incubated for another hour. The effect of Ang II (Sigma Aldrich,) on insulin release 
from isolated islets was determined at 0.1，1，10 and 100 nmol/l of Ang II. Ang II was 
added in the KRBB medium with 16.7 mmol/l glucose during the second hour of 
incubation. Specific Ang Il-receptor antagonists for ATi, losartan (Merck & Co., 
NJ, USA; 1 [iU) and for AT2, PD123319 (Sigma Co., St. Louis, MO, USA; 1 |aM) 
were administered 10 min before the Ang II treatment. After the incubation, the 
medium was collected for the measurement of insulin release using a Mouse Insulin 
ELISA Kit (Mercodia, Uppsala, Sweden). Figure 2-1 is a schematic diagram of the 
procedure for measurement of insulin release. 
54 
Di^ icategfixfscf IVkduntErnvBd 
10 islets ^ 
KPEB+1.7h1Vl^ ucxse 
Z^edficAr^blodfl^�Ang II) Change to high 
IVbdimcollectBdfor I Ixsatai J ^ucose 
measireniEnt of i n ^ n release — J l concentration 
Kra+ia7n1Vlc<iJ00se 
Figure 2-1 Schematic diagram of measurement of insulin release 
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2.3.2 Measurement of islet glucose oxidation rate 
Triplicate groups of ten islets were transferred to glass vials containing 100 |al of 
Kerbs Ringer Bicarbonate Buffer (KRBB) supplemented with glucose 
(Amersham-Pharmacia Biotech, Uppsala, Sweden) and non-radioactive glucose to a 
final glucose concentration of 1.7 or 16.7 mmol/1 glucose, respectively (spec. act. 0.5 
mCi/ mmol). To some vials Ang II was added to a final concentration of 100 nmol/l. 
The islet glucose oxidation rates during 90 min incubation at 37 °C (95 VoOilS °/oC02) 
were measured as described elsewhere [Andersson 1983]. Briefly, radioactive 
(i4C-glucose) is dried in vacuum centrifuge for 30 min and dissolved in 1.2ml low or 
high glucose solution. 100 # 1 of the radioactive glucose solution was put into each 
Jarret vial. Angll (lOOnmol/1) and/or losartan (1 ii mol/1) was added in both low 
and high glucose concentration vials. Islets were picked and washed in Hanks' 
solution and then 10 islets were put into each Jarret vial (triplicate each set). The 
Jarret vials were put into dry, clean glass vials that were gassed with (95 % O2/5 % 
CO2)，covered with lids. The vials were then incubated in 37 water bath with 
shaking for 90 min. After incubation, 100/zl of antimycin (Sigma Co., St. Louis, 
MO, USA) was injected into the Jarret vials with islets slowly, using a 27G needle 
and 1ml syringe to kill the P cells. Then 250 //1 ofhyamine (ICN Biomedicals Inc., 
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Aurora, OH, USA) was injected into the large glass vials with a 18G needle and 1ml 
syringe to trap the CO2. Lastly, 100//I phosphate buffer(pH 6.0): was injected into 
the Jarret vials with islets using a 27G needle and 1ml syringe to lower the pH. The 
vials were then incubated in 37 °C water bath for another 120 min (without shaking). 
5/ / I of the radioactive glucose solution (both low and high concentration) and 250 
jji 1 hyamine were put into 3 vials for standard control. After incubation, the Jarret 
vials were removed, and the glass vials filled with 5ml Ultima Gold (PerkinElmer 
Life Sciences, Boston, MA, USA) scintillation liquid. Amount of radioactive 
glucose oxidized was measured using a scintillation counter. Calculation of 
oxidized glucose content was shown as follow: 
1. Transformation factor = 5 x 16700 / *dpm Standard (pmol/dpm) 
2. Amount of oxidized glucose (pmol) 
=(dpm Sample - dpm Blank) x transformation factor 
*dpm=degradation per minute 
Figure 2-2 is a schematic diagram of the measurement of glucose oxidation 
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Figure 2-2. Schematic diagram for the measurement of glucose oxidation. 
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2.3.3 Measurement of islet (pro)msulin biosynthesis 
Duplicate groups of ten islets were incubated, with or without 100 nmol/1 Ang II， 
and/or losartan (1 弘 mol/1) at 37°C in 100 |il of KRBB containing 50 |aCi/ml of 
L-[4,5-3H]-leucine (Amersham-Pharmacia Biotech, Uppsala, Sweden) and 1.7 or 16.7 
mmol/1 glucose in an atmosphere of humidified air plus 5%C02. After 2 h, the islets 
were washed in buffer containing non-radioactive leucine (10 mmol/1) and sonicated 
in 200 of redistilled water. The amount of labeled (pro)insulin was determined by 
an immunoabsorption technique [Halban et al 1980]. Briefly, 1 0 o f the sonicated 
homogenates was taken out and put into glass tubes with 100^1 of glycine buffer 
with albumin and Triton X-100. Two positives and two negatives were set up for 
each sample. For the positives, 10 of anti-insulin serum (Chemicon Intemation 
Inc., Temecula, CA, USA) was added and for the negatives, 10//I of normal guinea 
pig serum was added. The samples were incubated for 1 hour in 37�C. Then, 50 
• , 
(X1 of rProtein A Sepharose (Amersham Biosciences, Uppsala, Sweden) was added 
to the samples and shaked in room temperature for 15 minutes. The-samples were ‘ 
then centrifuged and washed twice with 500//I Glycine buffer. The pellets were 
resuspend in 500 [i I Acetic acid with albumin and then poured into 6ml scintillation 
flasks. 4ml Ultima Gold (PerkinElmer Life Sciences, Boston, MA, USA) 
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scintillation liquid was added for each flask and the radioactivity counted by a 
scintillation counter. 
2.3.4 Measurement of Islet total protein synthesis 
As for insulin biosynthesis, duplicate groups of ten islets were incubated, with or 
without 100 nmol/l Ang II，and/or losartan (1 [i mol/1) at 37 °C in 100 \i\ of KRBB 
containing 50 [iCi/ml of L-[4,5-3H]-leucine (Amersham-Pharmacia Biotech, Uppsala, 
Sweden) and 1.7 or 16.7 mmol/l glucose in an atmosphere of humidified air plus 5 
%C02. After 2 h, the islets were washed in buffer containing non-radioactive leucine 
(10 mmol/l) and sonicated in 200 |al of redistilled water. The total protein 
biosynthesis was measured in trichloroacetic acid precipitates of the islet homogenate 
[Halban et al. 1980]. The samples after sonication were centrifuged and washed 
once with 500 p, 1 glycine buffer. The pellets were resuspend in 500 [i 1 acetic acid 
with albumin and then poured into 6ml scintillation flasks. 4ml Ultima Gold 
(PerkinElmer Life Sciences, Boston, MA, USA) scintillation liquid was added for 
each flask and the radioactivity counted by a scintillation counter. Figure 2-3 shows 
a schematic diagram for the measurement of islet (pro)insulin and protein 
biosynthesis. 
60 
Duplicate g o f s 
12iTinat37^(Cyoq) • • Islets VNBshedwth 
’ 
W«v\ith1.7M\/lcria7h1VI 自 UDoee : : scricatBdin2D0|i 
aid5D)ja/rTlcfM4S3|ileirire • redstillechAfiter 
I I 
H e t h c m ^ ； : feldhcmogen^ 
Labeled (prtjinaJin cfetenri 丨 tbcI by an Total prctein bo^rlhesis measuKi in 
irrmnoateapticntechiqLe tricHcrcaoeticacid predpitstes 
Figure 2-3 Schematic diagram for measurement of islet (pro)insulin and protein 
biosynthesis 
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2.4 Chronic losartan treatment 
Some of the transplanted mice were in random assigned to treatment with losartan (30 
mg X kg-i X day''; Merck & Co，Whitehouse Station, NJ) dissolved In their drinking 
water. The concentration of losartan in drinking water (0.13 mg/ml) to yield this dose 
of losartan was determined from pilot experiments (n=3), where the daily intake of 
water was in average 7 ml for each mouse during a one-week-period. 
2.5 Perfusion experiment of islet graft 
Grafts from transplanted mice were investigated one month posttransplantation for 
insulin secretion capacity to glucose, using a previously published protocol [Korsgren 
et al 1989]. Briefly, the graft-bearing left kidney was removed together with part of 
the aorta and inferior vena cava. The ureter and the renal vein were cut, whereas the 
aorta was cannulated and infused with a continuously gassed ( O 2 / C O 2 = 95:5) Krebs 
* . 
Ringer Bicarbonate Buffer (KRBB) supplemented with 2% (wt/vol) each of bovine 
serum albumin (BSA, fraction V, Miles Laboratories, Slough, U.K.) and dextran T70 
(Pharmacia, Uppsala, Sweden) and 2.8 or 16.7 mmol/1 glucose. The medium was 
administered at a rate of 1.0 ml/min without recycling for 60 min with a perfusion 
pressure of � 4 0 mmHg. The perfusion experiments started with a 15-min period 
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using a medium containing 2.8 mmol/1 glucose, followed by 30-min with 16.7 mmol/1 
glucose and finally 15-min with 2.8 mmil/l glucose again. In some experiments, Ang 
II (Sigma) or losartan (Merck) were added during the perfusion with the high glucose 
medium (16.7 mmol/1) at a concentration of 10 ng/ml and 100// g/ml respectively. A 
1.0 ml sample of the effluent medium was collected every fifth min, except for the 
first 10 min of perfusion with the high glucose concentration when samples were 
taken after 1-5, 7 and 10 min. The insulin concentration of the effluent samples 
were measured by ELISA (Mercodia, Uppsala, Sweden). The rate of insulin 
secretion was calculated by multiplying the insulin concentration in the sample by 
flow rate, giving values of insulin expressed as nanograms of insulin per minute. 
2.6 Insulin content of the islet graft 
After perfusion the graft was removed from the kidney and homogenized in 1000 " 1 
• • 
of acid-ethanol (0.18 mmol/1 HCL in 95 % [vol/vol] ethanol). The samples were 
extracted overnight at 4 followed by ELISA of insulin (Mercodia).‘ 
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2.7 Islet graft (pro)msulin and total protein biosynthesis 
Some of the transplanted mice were one month posttransplantation allocated to 
measurements of islet graft (pro)insulin and total protein biosynethesis as previously 
described (Section 2-3-3 & 2-3-4) [Korsgren et al 1989]. Briefly, explanted islet 
grafts were incubated with or without 1 ji mol/1 losartan (Merck), at 37 in 100 1 
of KRBB containing 50 {i Ci/ml of L-[4,5-3H]leucine (Amersham-Pharmacia 
Biotech, Uppsala, Sweden) and 16.7 mmol/l glucose in an atmosphere of humidified 
air plus 5 % CO2. After 2 hours, the islets were washed in buffer containing 
non-radioactive leucine (10 mmol/l) and sonicated in 200/zl of redistilled water. 
The amount of labeled (pro)insulin and total protein biosynthesis were determined as 
described in Section 2-3-3 and 2-3.4. 
2.8 Real-time RT-PCR analysis 
Real-time RT-PCR is a new technique to quantitate mRNA expression levels which 
requires minimal sample and no postreaction manipulation [Winer-e/ al 1999]. 
Briefly, real-time PGR monitors the degradation of a dual-labeled fluorescent probe 
(Tag-Man probe) in real time concomitant with PGR amplification. The 5, 
nucleolytic activity of Taq polymerase cleaves the probe, spatially separating the 5' 
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reporter fluorescent dye from the 3，quencher fluorescent dye, resulting in an 
increase in the emission spectra of the reporter fluorescent dye. These data are 
graphed as amplification plots. Figure 2-4 shows a schematic diagram of real-time 
PGR technique. In this study, real-time quantitative RT-PCR was performed using 
an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Foster 
City, Calif., USA) as validated before. Total RNA was extracted from pancreas or 
pools of all islets isolated from control and retrieved from transplanted mice (groups 
of 8-10 mice each), using the TRIzol reagent kit (Life Technologies, Gaithersburg, 
MD, USA) according to the manufacturer's instructions. Total RNA was also 
extracted from liver and kidney in order to study the relative abundance of islet 
mRNA compared to these tissues. The RNA was used as template in one-step Taq 
Man amplification reactions. 
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Figure 2-4. Schematic diagram showing the reaction in a real-time peR. 
Dark circle: quencher fluorescent dye; gray circle: "reporter fluorescent dye. 
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2.8.1 Design of primers and probes 
TaqMan primers and probes for Ao，ACE, ATi and AT2 were designed from mouse 
cDNA sequence using Primer Express Software purchased from Applied Biosystems 
Perkin-Elmer [Winer et al 1999]. Briefly, primers for each gene target were 
selected containing minimal internal structure (i.e., hairpins and primer-dimer 
formation as determined by the software) and having compatible Tm (i.e., each within 
1 °C of the other). Probes were selected such that their Tm was approximately 5-10 
higher than the matching primer pair. Table 2-1 depicts the brief details of RAS 
sequence of PGR primers and their specific probes, as well as corresponding cDNA 
sequence. 
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Table 2-1. Sequence of specific PGR primers and fluorescent probes for the RAS 
components, and p-actin employed for the real-time quantitative RT-PCR. Ao 
denotes angiotensinogen 
RAS g e n e S e q u e n c e g S I " ^ ' " ^ 
A T i Forward : CCA TTG TCC ACC CGA TGA AG 458-477 (s37484) 
Reverse : TGC AGG TGA CTT TGG CCAC 520-502 (s37484) 
Probe : CTC GCC TCC GCC GCA CGA 479-497 (s37484) 
AT2 Forward : CAG CAG CCG TCC TTT TGA TAA 176-196(U04828) 
Reverse : TTA TCT GAT GGT TTG TGT GAG CAA 256-233 (U04828) 
Probe : CAA CTG GCA CCA ATG AGT CCG CCT 205-228 (U04828) 
a c e Forward : TGA GAA AAG CAC GGA GGT ATC C 336-357 (M55333) 
Reverse : AGA GTT TTG AAA GTT GCT CAC ATC A 420-396 (M55333) 
Probe : ACC CTG AAA TAT GGC ACC CGG GC 364-386 (M55333) 
A o Forward : GAG GCA A AT CTG AGC AAC ATT G 1196-1216 (NM_007428) 
Reverse : GAG TTC GAG GAG GAT GCT ATT GA 1269-1247 (NM_007428) 
Probe : TGA CAC CAA CCC CCG AGT GGG A 1218-1239 (NM—007428) 
P-actin Forward : CCG TGA AAA GAT GAC CCA GAT C 267-288 (M12481) 
Reverse : CAC AGC CTG GAT GGC TAC GT 339-320 (M12481) 
Probe : TGA GAC CTT CAA CAC CCC AGC CAT G 294-318 (Ml2481) 
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2.8.2 Use of internal control 
Mouse p-actin RNA was used as internal control. The purpose of the internal 
control gene is to normalize the PCRs for the amount of RNA added to the reverse 
transcription reactions. Standard housekeeping genes such as p-actin are usually 
used as internal controls. The internal control gene is properly validated for each 
experiment to determine that gene expression is unaffected by the experimental 
treatment. 
2.8.3 RT-PCR reaction 
TaqMan reactions were set up in a reaction volume of 25 by using components 
supplied in a Taq Man PGR reagent kit. Each reaction consisted of 12.5 i^l PGR 
master mix, 18 i^mole of each amplification primer, 25 \xM corresponding Taq Man 
probe and 30 ng RNA template. Each sample was run in duplicate with initial 30 
min at 48 °C and 10 min at 95 °C for reverse transcription, followed by 40 cycles at 
95 °C for 15 sec and at 60 for 1 min. Amplification data were collected by the 
7700 Sequence Detector and analyzed by use of the Sequence Detection System 
software. The RNA concentration was determined from the threshold cycle (CT) at 
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which fluorescence is first detected, the cycle number being inversely related to RNA 
concentration. The brief details of RAS sequence of PCR primers and their specific 
probes, as well as corresponding cDNA sequence, were listed in Table2-1. 
2.8.4 Calculation using the comparative C t method 
The fold changes in RAS mRNAs by islet transplantation were calculated using the 
2-mctmethod [Livak and Schmittgen 2001]. In the real-time RT-PCR, a value, Cj 
is calculated based on the time (measured in PCR cycle numbers) at which the 
reporter fluorescent emission increases beyond a threshold level. The C t value is 
correlated to input target mRNA levels; a greater quantity of input mRNA target 
results in a lower CT value, as a result of requiring less PCR cycles for reporter 
fluorescent emission intensity to reach the threshold. The ACj value is calculated 
by the subtraction of the p-actin CT from each sample CT. The AACT value is 
• . 
calculated by subtraction of the control ACT from each transplanted sample ACJ. 
AACt 
The expression relative to control is calculated using the equation 2" 丁. 
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2.9 Western blot analysis 
Islets were isolated from control or retrieved from transplanted mice. Protein of 
300 islets was extracted using CytoBuster^'^ Protein Extraction Reagent (Novagen, 
Darmstadt, Germany). Protein content of lysates was determined by a Bio-Rad 
protein assay kit (Bio-Rad, Munich, Germany). Western blot analysis of 
AT 1-receptor protein expression was performed according to our previously 
described protocol [Leung et al 2000]]. Briefly, proteins (10 ^ig/lane) were 
subjected to electrophoresis on a 12 % (wt/vol) polyacrylamide. The blotted protein 
was saturated with 5 % (wt/vol) of skimmed milk in phospate-buffered saline (PBS; 
pH 7.4) and 0.1 % (vol/vol) of Tween 20 for 1 hour at room temperature. The 
membrane was sequentially incubated in rabbit anti-ATi serum (1:300 dilution) 
overnight at 4 °C and a peroxidase-labelled anti-rabbit IgG antibody (1:1300 dilution) 
for 1 hour at room temperature. The positive signal was revealed using ECL plus 
• . 
Western blotting detection reagents and autoradiography film (Amersham, 
Buckinghamshire, UK). The chemiluminescence intensity of the bands was 




Immimohistochemistry coupled with a double-staining technique [Lam and Leung 
2002; Fung et al. 2002] was employed to determine the specific localization of 
AT 1-receptor in islets. Whole pancreas or isolated islets were fixed with 4 % 
(vol/vol) cold paraformaldehyde and embedded in paraffin. Sections (5 陣 thick) 
were mounted on glass slides, deparaffinized and processed for indirect 
immunofluorescent double staining. After several washes with PBS (pH 7.4), each 
slide was incubated with 4 % (wt/vol) Normal Donkey serum (Jackson 
ImmunoResearch, PA, USA) for 60 minutes at 37 Excess blocking solution was 
removed and the slide was incubated overnight at 4 °C with rabbit anti-ATi serum 
(Santa Cruz Biotech., Santa Cruz, CA, USA), diluted to 1:25, and with goat 
anti-insulin serum (Santa Cruz Biotech.), diluted to 1:50. After 3 washes with PBS, 
the primary antibodies were detected using an anti-rabbit antibody labeled with 
* , 
Rhodamine (AT 丨-receptor) and an anti-goat antibody labeled with 
Aminomethylcoumarin Acetate (insulin) (Jackson ImmunoResearch, -PA, USA) at 
room temperature for one hour. Preadsorption and omission of primary antibodies 
were used as negative controls. Positive immunostaining for ATi (red) and for 
insulin (blue) was examined with a fluorescent microscope equipped with a DC 200 
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digital camera (Leica Microsystems). 
Semiquantitative assessment of islet P-cell mass was performed by determining the 
percentage proportion of area per islet section occupied by the positive staining (blue) 
within each islet (x40 objective). A total of 10 islets per mouse pancreas were 
analyzed. 
2.11 Statistical data analysis 
Results were expressed as means 土 SEM for all groups. Multiple comparisons 
between data were performed using ANOVA followed by Tukey's test, or, when 
comparisons only were made toward control, by Dunnett's test. When only two 
groups were compared, probabilities (P) of chance differences between the 
experimental groups were calculated with Student's unpaired two-tailed t-test. For all 
comparisons, P<0.05 was considered statistically significant. For Western blot 
analysis, data were normalized as a percentage of control. For real-time RT-PCR, the 
relative expression was normalized as percentage of P-actin and calculated using the 
comparative C t method of 2-么"^匚丁，^s described previously. 
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Chapter 3 Results 
3.1 Effects of Angiotensin II and Losartan on islet insulin release 
3.1.1 Insulin release from normal islets 
Insulin release from the isolated islets was markedly enhanced as expected when 
changing glucose concentration in the incubation medium from 1.7 to 16.7 mmol/l 
(Fig. 3-1). However, the glucose-stimulated insulin release was dose-dependently 
decreased by the addition of 0.1, 1, 10 and 100 nmol/l of Ang II (Fig. 3-1). At the 
highest used concentration of Ang II (100 nmol/l), the glucose-induced insulin 
release could be completely prevented. Pretreatment of isolated islets with 1 |amol/l 
of losartan, a specific antagonist for the ATi-receptor, before the addition of Ang II 
(100 nmol/l) completely restored the insulin secretion to the glucose-stimulated level 
(Fig. 3-2). However, pretreatment with 1 |^mol/l of PD123319, a specific 
antagonist for the AT2-receptor had no effect on glucose-stimulated insulin release 
(data not shown). On the other hand, losartan per se had no effect on 
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Figure 3-1. Insulin release from isolated mouse islets in the presence of 1.7 (low; L) 
or 16.7 mmol/1 (high; H) glucose. Ang II was applied at concentrations of 0.1, 1, 10 
and 100 nmol/1 at the higher glucose concentration. All data are expressed as means 
土 SEM for four experiments in each group. * denotes P<0.05 when compared to 
islets exposed to 16.7 mmol/1 glucose only. 
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Figure 3-2. Effects of losartan (Los, l|amol/l) and Ang II (100 nmol/l) on the glucose 
-stimulated (16.7 mmol/1) (high; H) insulin release from isolated islets. All data are 
expressed as means 土 SEM for four experiments in each group. * denotes P<0.05 
when compared to islets exposed to 16.7 mmol/1 glucose only. 
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3.2 Effects of Angiotensin II and Losartan on islet glucose oxidation rate, 
(pro)msulin and total protein biysynthesis 
3.2.1 Glucose oxidation rate of isolated normal islets 
Islet glucose oxidation rate was, as the insulin release, markedly higher at 16.7 
mmol/1 than 1.7 mmol/1 glucose (Fig. 3-3). Addition of Ang II (100 nmol/1) to the 
islets during incubation did not affect either the islet glucose oxidation rate at 1.7 or 
16.7 mmol/1 glucose. 
I 
3.2.2 (Pro)insulm and total protein biosynthesis of isolated normal islets 
On the other hand, islet (pro)insulin and total protein biosynthesis were, as the 
insulin release, markedly higher at 16.7 mmol/1 than 1.7 mmol/1 glucose (Fig. 3-4 
and Fig. 3-5). Islet (pro)insulin biosynthesis at 16.7 mmol/1 glucose but not at 1.7 
mmol/1 glucose was inhibited by 100 nmol/1 Ang II (Fig. 3-4). Islet total protein 
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Figure 3-3. Influence of Ang II (100 nmol/1) on the glucose oxidation rate in isolated 
mouse islets exposed to 1.7 (low; L) or 16.7 mmol/l (high; H) glucose. All data are 
expressed as means±SEM for 9 experiments in each group. 
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Figure 3-4. Influence of Ang II (100 nmol/l) on the (pro)insulin biosynthesis in 
isolated mouse islets exposed to 1.7 (low; L) or 16.7 (high; H) mmol/1 glucose. All 
data are expressed as means±SEM for 6 experiments in each group. * denotes P<0.05 
when compared to corresponding islets exposed to 1.7 mmol/1 glucose, whereas # 
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Figure 3-5. Influence of Ang II (100 nmol/1) on the total protein biosynthesis in 
isolated mouse islets exposed to 1.7 (low; L) or 16.7 (high; H) mmol/1 glucose. All 
data are expressed as means±SEM for 6 experiments in each group. 
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3.3 Regulation of RAS components by islet transplantation 
3.3.1 Expression of RAS components in endogenous islets and transplanted 
islets 
The expression of several major RAS components, namely ATi- and AT2-receptors, 
ACE and Ao, were examined and compared using real-time quantitative RT-PCR 
coupled with the comparative method in endogenous and transplanted islets. 
mRNAs for all the components studied were expressed in endogenous islets (Table 
3-1). When compared to endogenous islets, the relative expression of mRNAs for 
ATi to p-actin was increased by about 3- fold in transplanted islets (Fig. 3-6). In 
contrast, the relative expression of mRNAs for AT� to P-actin was down-regulated to 
approximately one third in transplanted islets (Fig. 3-7). The expression of mRNA 
for ACE in endogenous islets did not differ significantly from transplanted islets (Fig. 
3-8) while the expression of angiotensinogen mRNA in transplanted islets was lower 
than in endogenous islets (Fig. 3-9). ‘ 
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Table 3-1. Data on the expression of RAS components in endogenous and 
transplanted pancreatic islets using the comparative Cj method. 
RAS gene C t " A C / A A C / Expression relative 
to control “ 
Transplanted f^actin 16.72 土0.31 
ATI 23.82±0.66 7.1±0.75 -1.47±0.72 2.77 
AT2 29.96土0.60 13.24土0.64 +1 .70士 1 .20 0.31 
ACE 2 2 . 3 4 ± 0 . 4 7 5 . 6 2 ± 0 . 5 9 +0 . 94土0 . 88 0 . 5 2 
Ao 26.05±0.50 9.33±0.56 +1.36±0.66 0.39 
Control j3-actm 15.00 土 0.62 
ATi 23.58±0.82 8.57土 0.29 
AT2 26.54土0.30 11.54土 0.80 
ACE 19.69 士0.60 4.69土 0.75 
Ao 22.98±0.50 7.97±0.15 
Ao Angiotensinogen 
a The average of the C t data for each sample 
b The ACT value is calculated by the subtraction of the p-actin CT from each sample 
CT 
c TheAACj value is calculated by subtraction of the control ACT from each 
transplanted sample ACT 







囊 1 • • 
Endogenous Transplanted 
Figure 3-6. Real-time RT-PCR analysis of the mRNA expression of A. ATi receptor; 
in endogenous and transplanted mouse islets. The relative expression was normalized 
as percentage of p-actin calculated using the comparative Cj method of 2-么八 丁 (Table 
2). All data are expressed as means 土 SEM for four experiments in each group. * 
denotes P<0.05 when compared to endogenous islets. 
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Figure 3-7. Real-time RT-PCR analysis of the mRNA expression of AT2 receptor in 
endogenous and transplanted mouse islets. The relative expression was normalized as 
percentage of P-actin calculated using the comparative Cj method of (Xable 2). 
All data are expressed as means 土 SEM for four experiments in each group. * 




II 壽 • • r Mm 
Endogenous Transplanted 
Figure 3-8. Real-time RT-PCR analysis of the mRNA expression of ACE in 
endogenous and transplanted mouse islets. The relative expression was normalized as 
percentage of P-actin calculated using the comparative CT method of (Table 2). 
All data are expressed as means 土 SEM for four experiments in each group. * 
denotes P<0.05 when compared to endogenous islets. 
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Figure 3-9. Real-time RT-PCR analysis of the mRNA expression of angiotensinogen 
in endogenous and transplanted mouse islets. The relative expression was normalized 
as percentage of P-actin calculated using the comparative Ct method of 2'崎(Table 
2). All data are expressed as means 土 SEM for four experiments in each group. * 
denotes P<0.05 when compared to endogenous islets. 
• . 
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3.3.2 Localization of ATi-receptor in endogenous islets 
A technique with double immimostaining was employed for precise localization of 
AT 1-receptors in the pancreatic islets (Fig. 3-10). The localization of ATi-receptors 
(Fig. 3-1 OA) to the insulin secreting (3 cells (Fig. 3-lOB) was identified by an overlay 
of immimoreactivity for insulin and the ATi-receptor (Fig. 3-lOC). Specificity of the 
immunoreactivity was validated by control experiments with preadsorption and 
omission of primary antibody for the ATi-receptor (Fig. 3-lOD). 
• • 
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Figure 3-10. Immunohistochemical localization of ATi receptors and insulin in 
isolated mouse pancreatic islets. (A). Isolated islet stained for ATi receptors (red). 
(B). Islet stained for insulin (blue). (C). Immimoreactivity for that ATi receptor was 
co-localized with that for insulin in the islet beta-cells (purple). (D). Negative control 
with preadsorption and omission of primary antibodies. Magnification: 40 x. 
Bar = 40)j,m. 
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3.3.3 Expression of ATi-receptor protein in endogenous and transplanted islets 
Western blot analysis was carried out to confirm that findings of AT i-receptor mRNA 
in endogenous and transplanted islets were reflected also at the protein level (Fig. 
3-11). A major protein band of about 50 kDa was expressed both in endogenous and 
transplanted islets; in the latter case this was a band of strong intensity (Fig. 3-11 A). 
This molecular mass (50 kDa) was in close agreement with that of ATi-receptor 
protein in mouse kidney, which was used as a positive control for the expression of 
the ATi-receptor. The relative expression of ATi-receptor protein in transplanted 
islets was upregulated two-fold when compared to that in endogenous islets, as 
determined by image analysis (Fig. 3-1 IB). 
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Figure 3-11. Western blot analysis of ATi receptor protein from endogenous and 
transplanted mouse pancreatic islets. A. Representative gel image. Lane 1 shows 
protein of the ATi receptor from mouse kidney. A major band of about 50 kDa was 
detected. Lanes 2 and 3 show the expression of the ATi receptor in protein of .10 昭 
from isolated endogenous and transplanted islets, respectively. B. The relative 
expression of the ATi receptor protein (%) in transplanted islets when compared to 
endogenous islets. All data are expressed as means 土 SEM for four experiments. * 
denotes P<0.05 when compared to endogenous islets. 
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3.3.4 Relative abundance of RAS components in kidney and liver 
As calculated from the Ct (Table 3-1), the relative abundance of different mRNA 
studied were 0.9，1.1 and 1.2 for AT2, Ao and ACE respectively as compared to ATi 
expression being as 1. On the other hand, the relative abundance of ATi and AT2 
expression in the mouse islets was about 70%, when compared with that in the liver 
and kidney based on the calculation from the Ct using p-actin as internal control 
(Table 3-2). 
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Table 3-2. Relative abundance of different RAS components in mouse islet, liver 
or kidney normalized to P-actin. 
Relative abundance (normalized to p-actin) AT) AT2 Ao ACE 
Islet 0.6193 0.5655 0.6530 0.7625 
Liver 0.8465 0.5645 0.8023 0.6480 
Kidney 0.8362 0.6218 0.7258 0.8410 
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3.3.5 Insulin release from perfused transplanted islet graft 
A first-phase insulin release in response to stimulation with a high glucose 
concentration (minutes 15-20) and a sustained second phase (minutes 21-45) was 
observed from otherwise untreated islet grafts. Addition of Ang II to the high 
glucose medium during perfusion attenuated the first phase of glucose-stimulated 
insulin release, and also decreased insulin release during early second phase (Fig. 
3-12). When losartan was added to the high glucose medium, a markedly improved 
early phase of insulin release with a peak value more than twice that in control grafts 
was observed (Fig. 3-13). In contrast to this, the second phase of insulin release 
was decreased in these acute losartan-treated grafts. Islet grafts obtained from 
transplanted animals subjected to losartan treatment throughout the first 
posttransplantation month had both a lower first and second phase of insulin release 
compared to control grafts. The insulin content of the islet grafts subjected to 
chronic losartan was higher than in control grafts (4568+211 vs 3105±202 ng 
insulin/graft, respectively. 
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Figure 3-12. Insulin concentration in effluent medium collected from perfused islet 
graft bearing kidney of C57BL/6 mice. After 15 min of perfusion with a medium 
containing 2.8 mmol// D-glucose, insulin secretion was stimulated with a 30-min 
period with 16.7 mmol/1 D-glucose (bar), followed by 15 min with 2.8 mmol/1 
D-glucose. The influence of additon of Ang II (10 nmol/1; empty boxes) to the high 
glucose medium was compared to the perfusion of control islet grafts (closed boxes). 
All values are given as means 土 SEM for 6-8 animals. p<0.05 for all observations 
between 15-25 min when compared to control grafts. All comparisons were made 
using ANOVA. 
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Figure 3-13. Insulin concentration in effluent medium collected from perfused islet 
graft bearing kidney of C57BL/6 mice. After 15 min of perfusion with a medium 
containing 2.8 mmol// D-glucose, insulin secretion was stimulated with a 30-min 
period with 16.7 mmol/1 D-glucose (bar), followed by 15 min with 2.8 mmol/1 
D-glucose.The influence of addition of the Ang II type 1 receptor inhibitor losartan 
(100|ig/ml (empty boxes) to the high glucose medium, or pretreatment of the 
amimals with losartan (30 mg x kg"^  x day'^  dissolved in the drinking water; empty 
triangles) was compared to the perfusion of control islet grafts (closed boxes). Same 
controls are used in both 3-12 and 3-13, as well as the different scales on the 
ordinates. All values are given as means 土 SEM for 6-8 animals. p<0.05 for acute 
losartan treatment at min 16-18; acute losartan treatment at min 20-45 and losartan 
pretreatment at min 16-50 when compared to control grafts. All comparisons were 
made using ANOVA. 
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3.3.6 (Pro)insulin and total protein biosynthesis of transplanted graft 
Exposure to losartan 1 |imol/l did not affect (pro)insulin biosynthesis in retrieved 
islet grafts at high glucose concentration (16.7 mmol/l) (389 ± 108 vs 427 ±_108 dpm 
X islet graft"^ ^  min'^  for control and losartan exposed grafts, respectively; n=8 in 
both groups). (Fig. 3-14) Likewise, total protein biosynthesis in the islet grafts 
were not affected by losartan at the high glucose concentration (803 + 77 vs 937 + 
231 dpm X islet graft"^" 120 min'' for control and losartan exposed grafts, respectively; 
n=7 in both groups) (Fig. 3-15). 
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Figure 3-14. Influence of losartan (Los，1 |imol/l) on the (pro)insulin biosynthesis in 
islet grafts exposed to 16.7 (high; H) mmol/1 glucose. All data are expressed as 





专 三 丁 
C CM 
1000- a m J L i m 
i j f I H H 
r • m 
0-1 ^ 
H H + Los 
Figure 3-15. Influence of losartan (Los, 1 |^mol/l) on the total protein biosynthesis 
in islet grafts exposed to 16.7 (high; H) mmol/1 glucose. All data are expressed as 
meansiSEM for 7 experiments in each group. 
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3.4 Effects of Ang II and Losartan on islets from diabetic mice 
3.4.1 Expression of RAS components in diabetic pancreas 
The expression of several major RAS components, namely ATi- and AT2-receptors, 
a c e and Ao, were examined and compared using real-time quantitative RT-PCR 
coupled with the 2-mct comparative method in m+/+db (control) and +db/+db 
(diabetic) pancreas. mRNAs for all the components studied were expressed in 
control and diabetic mice pancreas (Table 3-3). When compared to control, the 
relative expression of mRNAs for ATi to P-actin in diabetic mice pancreas was 
increased by about 2- fold (Fig. 3-16). The relative expression of mRNAs for AT2 
to P-actin was up-regulated by approximately 4.5 fold in diabetic mice pancreas (Fig. 
3-17). The expression of mRNA for angiotensinogen mRNA was also increased by 
almost 7 fold in diabetic mice pancreas (Fig. 3-18)，while the expression of ACE in 
diabetic mice pancreas was down-regulated to about three-quarter of that in control 
mice pancreas (Fig. 3-19). ‘ 
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Table 3-3. Data on the expression of RAS components in control and diabetic mouse 
pancreas using the comparative Ct method. 
RAS gene Or® A C / A A C / Expression relative 
to control ^ 
Control P-actin 20.19 ±0.67 
ATI 2 1 . 5 1 土 0 . 4 4 1 . 5 1 ± 1 . 3 3 
AT2 35.08±0.97 14.87+0.91 
ACE 31.77 土0.75 11.68士 0.69 
Ao 24.78土 0.61 4.83 士 0.49 
Diabetic ^actin 20.22土 1.06 
AT I 2 1 . 5 6 土 0 . 6 1 0 . 6 5 ± 1 . 4 5 -0.87土 0.56 1.94 
AT2 3 2 . 8 4 土 0 . 9 6 1 2 . 9 5 士 0 . 9 9 - 1 . 9 2 ± 0 . 6 9 4 . 1 7 
a c e 29.76土0.93 8.99土0.37 -2.69士0.53 6.84 
Ao 2 5 . 3 4 ± 0 . 8 8 5 . 3 6 ± 0 . 4 0 +0 .53土 0 . 3 0 ^ 
Ao Angiotensinogen 
“ The average of the Cj data for each sample 
b The ACT value is calculated by the subtraction of the p-actin CT from each sample 
CT 
c TheAACi value is calculated by subtraction of the control ACT from each 
transplanted sample ACT 








Figure 3-16. Real-time RT-PCR analysis of the mRNA expression of ATi receptor in 
control (m+/+db) and diabetic (+db/+db) mouse pancreas. The relative expression 
was normalized as percentage of p-actin calculated using the comparative Ct method 









Figure 3-17. Real-time RT-PCR analysis of the mRNA expression of AT2 receptor in 
control (m+/+db) and diabetic (+db/+db) mouse pancreas. The relative expression 
was normalized as percentage of P-actin calculated using the comparative Ct method 
of All data are expressed as means 土 SEM for six experiments in each group. 
* denotes P<0.05 when compared to control islets. 
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Figure 3-18. Real-time RT-PCR analysis of the mRNA expression of 
angiotensinogen in control (m+/+db) and diabetic (+db/+db) mouse pancreas. The 
relative expression was normalized as percentage of P-actin calculated using the 
comparative Ct method of 2-^。丁 ^11 data are expressed as means 土 SEM for six 
experiments in each group. * denotes P<0.05 when compared to control islets. 
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Figure 3-19. Real-time RT-PCR analysis of the mRNA expression of ACE in control 
(m+/+db) and diabetic (+db/+db) mouse pancreas. The relative expression was 
normalized as percentage of p-actin calculated using the comparative Ct method of 
2-aaCt . All data are expressed as means 土 SEM for six experiments in each group. * 
denotes P<0.05 when compared to control islets. 
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3.4.2 Localization of ATi receptors in diabetic pancreas 
A technique with double immunostaining was employed for precise localization of 
AT 1-receptors in the pancreatic islets of control and diabetic mouse pancreas (Fig. 
3-9). Immunohistochemical staining for ATi receptor and p-cell marker insulin 
were intense in control islets. (Fig.3-20A and B). By comparison, staining for ATi 
receptor and insulin in diabetic islets were diffusing but with stronger intensity. 
(Fig.3-20 C and D). Semiquantitative assessment of islet p-cell was performed by 
determining the percentage proportion of area per islet section occupied by the 
positive staining (blue) within each islet (x40 objective). A total of 10 islets per 
mouse pancreas were analyzed. There was an overall reduction in the percentage of 
proportional area positively stained for insulin in diabetic islets (control, 50.60±1.18; 
diabetic, 24.34土0.77; p<0.05) 
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Figure 3-20. Immunohistochemical localization of ATi receptors and insulin in 
mouse pancreatic islets. (A) Pancreatic islet of control (m+/+db) mouse stained for 
insulin (blue) and (B) stained for ATi receptors (red). (C) Pancreatic islet of diabetic 
(+db/+db) mouse stained for insulin (blue), and (D) stained for ATi receptors (red). 
(E&F) Negative control with the omission of primary antibodies. Magnification: 40 x. 
Bar = 40|im. 
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3.4.3 Insulin release from islets of type 2 diabetic mice 
For m+/+db (control) mice, insulin release from the isolated islets was markedly 
enhanced as expected when changing glucose concentration in the incubation 
medium from 1.7 to 16.7 mmol/1 (Fig. 3-21). At the highest used concentration of 
Ang II (100 nmol/1), the glucose-induced insulin release could be completely 
prevented. Pretreatment of isolated islets with 1 jimol/l of losartan, a specific 
antagonist for the ATi-receptor, before the addition of Ang II (100 nmol/l) 
completely restored the insulin secretion to the glucose-stimulated level. On the 
other hand, losartan per se had no effect on glucose-stimulated insulin secretion (Fig. 
3-21). 
For +db/+db (diabetic) mice, insulin release from the isolated islets was also 
enhanced when changing glucose concentration in the incubation medium from 1.7 
to 16.7 mmol/1 (Fig. 3-22). At the highest used concentration of Ang II (100 
nmol/1), the glucose-induced insulin release could be completely prevented. 
Pretreatment of isolated islets with 1 ^imol/l of losartan, a specific antagonist for the 
ATi-receptor, before the addition of Ang II (100 nmol/l) not only completely restored 
the insulin secretion to the glucose-stimulated level, but also increased insulin release 
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to a level higher than that with high glucose alone. Losartan per se increased the 
insulin release to a significantly even higher extend (Fig. 3-22). 
When combining Fig. 3-21 and Fig. 3-22, it can be seen that the level of insulin 
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Fig.3-21. Effects of losartan (Los, l|imol/l) and Angll (100 nmol/l) on insulin release 
from isolated islets of control mouse (m+/+db) in the presence of 1.7 (low; L) or 16.7 
mmol/1 (high; H) glucose. *denotes p<0.05 when compared to islets exposed to 1.7 
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Fig.3-22. Effects of losartan (Los, liimol/l) and Angll (100 nmol/l) on insulin release 
from isolated islets of diabetic mouse in the presence of 1.7 (low; L) or 16.7 mmol/l 
(high; H) glucose. *denotes p<0.05 when compared to islets exposed to 1.7 mmol/l 
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Figure.3-23. Comparison of the effects of losartan (Los, 1 iamol/1) and Ang II (100 
nmol/1) on insulin release from control (m+) and diabetic (+db) mouse islets, in the 
presence of 1.7 (low; L) or 16.7 mmol/1 (high; H) glucose.. *denotes p<0.05 when 
compared to islets exposed to 1.7 mmol/l glucose only. #denotes ;?<0.05 when 
compared to islets exposed to 16.7 mmol/l glucose only. 
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3.4.4 (Pro)msulin and total protein biosynthesis of islets from type 2 diabetic 
mice 
Islet (pro)insulin biosynthesis was, as the insulin release, markedly higher at 16.7 
mmol/l than 1.7 mmol/l glucose (Fig. 3-24 & 3-25). Islet (pro)insulin biosynthesis 
at 16.7 mmol/l glucose but not at 1.7 mmol/l glucose was inhibited by 100 nmol/l 
Ang II (Fig. 3-24). At the highest used concentration of Ang II (100 nmol/l), 
insulin biosynthesis could be completely prevented. Pretreatment of isolated islets 
with 1 |imol/l of losartan, a specific antagonist for the ATi-receptor, before the 
addition of Ang II (100 nmol/l) completely restored the insulin biosynthesis to the 
glucose-stimulated level. Losartan per se increased the insulin biosynthesis to a 
level higher than that with high glucose alone (Fig. 3-25). By Comparing the 
effects of losartan on (pro)insulin biosynthesis from control and diabetic mouse islets, 
it can be seen that glucose-stimulated insulin biosynthesis from diabetic mouse islets 
was lower than that from control mouse islet. However, addition of Losartan could 
almost restore the glucose-stimulated insulin biosynthesis to a level similar to that of 
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Fig.3-24 Effects of losartan (Los, ljimol/1) and Angll (100 nmol/l) on (pro)ihsulin 
biosynthesis from isolated islets of control mouse (m+/+db) in the presence of 1.7 
mmol/1 (low; L) or 16.7 mmol/1 (high; H) glucose. *denotes p<0.5 when compared to 
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Fig.3-25 Effects of losartan (Los, l|amol/l) and Angll (100 nmol/1) on (pro)insulin 
biosynthesis from isolated islets of diabetic mouse (+db/+db), in the presence of 1.7 
mmol/1 (low; L) or 16.7 mmol/1 (high; H) glucose. *denotes p<0.5 when compared to 
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Fig.3-26 Comparison of the effects of losartan (Los, 1 }imol/l) and Ang II (100 
nmol/1) on (pro)insulin biosynthesis from control and +db/+db mouse islets, in the 
presence of 1.7 (low; L) or 16.7 mmol/1 (high; H) glucose, ^denotes p<0.5 when 
compared to islets exposed to 1.7 mmol/1 glucose only. 
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Chapter 4 Discussion 
4.1 Effect of angiotensin II and losartan on islet insulin release 
Ang II is the active vasopressor derived from the activation of the RAS. It is an 
octapeptide (MW 1045) and is generated from its inactive precursor Ang 1. The 
majority of circulating Ang II is derived from the activity of angiotensin-converting 
enzyme (ACE). The major effects of Ang II are selective stimulation of aldosterone 
in the adrenal cortex with resultant salt and water retention, vasoconstriction and 
ultimate promotion of a hypertrophic response within the myocardium and vascular 
smooth muscle cells, and promotion of cell growth and differentiation within smooth 
muscle and cardiac cells [Katz 1990]. Studies have shown that a basal 
intra-pancreatic production of Ang II occurs in the canine pancreas in concentrations 
several times greater than those measured in peripheral blood [Chappell et al 1991]. 
Its receptors in the pancreas are found on both endocrine, exocrine and vascular 
tissue, and are mainly AT2 receptor and ATi receptors [Chappell et al 1992]. 
Furthermore, a basal intra-pancreatic production of Ang II occurs also in the rat 
pancreas and this locally produced Ang II can suppress both whole pancreatic and 
islet blood flow [Carlsson et al. 1998]. 
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In that study, islet blood flow changes were associated with changes also in insulin 
release from the pancreatic islets. The effects of the Ang II on insulin release were 
made in pancreas with an intact vascular system by measuring insulin concentrations 
in the effluents from isolated perfused rat pancreata. Results showed that Ang II 
delayed the first phase of insulin release in response to glucose stimulation [Carlsson 
et al. 1998]. The data concluded that the pancreatic RAS might play a pivotal role 
in regulating islet blood perfusion, thereby affecting insulin release by the islet cells. 
As the identity of Ang II receptors on the pancreatic yS cells has not been elucidated 
at that time, vasoconstriction in the pancreatic islets was considered the most likely 
mechanism for these observations. 
To further elucidate the potential effects and mechanism of Ang II on islet insulin 
release, we employed the technique of islet isolation from the pancreas. We then 
tested the effects of Ang II coupled with its specific ATi receptor antagonist, losartan 
on islet insulin release in response to glucose stimulation by measuring insulin 
concentrations in the incubation medium. In the presence study, Ang II induced a 
dose-dependent and marked decrease of glucose-stimulated insulin release in isolated 
pancreatic islets, indicating that Ang II plays an important role in direct inhibition of 
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islet insulin secretion. With the highest dose of Ang II (100 mmol/1) used in the 
present study, the glucose-stimulated insulin secretion was completely abolished. 
However, this inhibitory effect could be fully restored by pretreatment of the islets 
with the specific ATi. receptor antagonist, losartan (Fig. 3-1 & 3-2). 
In contrast to the marked effects of Ang II on insulin release from mouse pancreatic 
islets as observed in the present study, exposure of the isolated rat islets to Ang II at a 
similar dose had no effects on insulin release in a previous study [Dunning et al 
1984]. The discrepancy of results could be due not only to the species difference 
but also to the different techniques employed. In this respect, the present study 
examined the influence of Ang II on glucose-stimulated (16.7 mmol/1 glucose) 
insulin release, whereas the effect of Ang II on insulin release was studied at low 
glucose concentration (5.6 mmol/1) in previous study [Dunning et al. 1984]. The 
currently employed approach with studies of isolated islets excluded that the 
inhibitory actions of Ang II on insulin release were solely attributable to its 
vasoconstrictor actions in the pancreatic islets [Carlsson et al 1998]. • The 
inhibitory effect of Ang II on glucose-stimulated insulin secretion from isolated islets 
was due, at least partly, to the decrease in (pro)insulin biosynthesis (Fig. 3-4). In 
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contrast, islet glucose oxidation rate was unaffected by Ang II (Fig. 3-3), indicating 
that the suppressive action of Ang II on glucose-stimulated insulin secretion appeared 
not to be of altered glucose oxidation. It has previously been shown that Ang 
Il-receptors could influence prostaglandin synthesis, which in turn may modulate 
insulin secretion [Jaiswal et all 1984; Kelly & Laychock 1981]. Whether the 
inhibitory actions of Ang II on insulin release from isolated islets are also mediated 
by this mechanism remains to be determined. 
4.2 Existence of local RAS in pancreatic islets 
In recent years, the existence of a local angiotensin-generating system in multiple 
tissue organs has been demonstrated [Campbell & Habener 1986; Campbell 1987]. 
• . 
This implies that locally produced Ang II exerts local actions from such diverse 
targets as the heart [Phillips et al 1993], adrenals [Wang et al 1992] and gonads 
[Leung & Semia 2003] to the pancreas recently reviewed [Leung & Carlsson 2001]. 
Previous studies have demonstrated the presence of such a local system in the 
pancreas of various species, including the dog [Chappell et al 1991], rat [Leung et al. 
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1997; Leung et al. 1999], mouse [Leung et al. 1998] and human [Tahmasebi et al 
1999]. Available data suggest a potential role for the angiotensin-generating system 
in regulating ductal anion secretion in the exocrine pancreas [Leung & Chappell 
2003; Fink et al. 2002]. Nevertheless, the potential presence and role of an 
angiotensin-generating system in the pancreatic islets remains largely unexplored. 
Indications for a role of Ang II in islets were provided by a perfusion study of whole 
pancreata, whereby the first phase of glucose-stimulated insulin release was 
markedly inhibited by Ang II [Carlsson et al 1998]. However, this finding was 
solely attributable to the vasoconstrictor action of Ang II’ which caused a decrease of 
islet blood flow in the pancreas. 
The present study, therefore, aimed specifically to investigate the existence of an 
angiotensin-generating system in the pancreatic islets. The present study provided 
evidence for the existence of an angiotensin-generating system in the islets by 
demonstrating the expression of several components (ATi and AT2 receptors, ACE, 
and Ao) in the pancreatic islets (Fig. 3-6 to 3-9). Of particular importance in this 
context is the presence of Ao, which constitutes a mandatory component for a local 
angiotensin-generating system. The existence of such a system makes a local 
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production of Ang II probable, which produces its concentrations several times 
greater than those measured in peripheral blood. 
In addition, the AT i-receptors were localized specifically to the islet p cells as 
evidenced by double immunofluorescence staining in the present study, further 
indicating that the inhibitory action of Ang II was mediated through the ATi-receptor 
located in the islet P cells (Fig. 3-10). Previous studies have shown that receptors 
for Ang II have also been identified in the animal pancreatic islets [Leung & 
Carlsson 2001; Ghiani & Masini 1995], but at least in rat, they were localized 
preferentially to the surface of a and 6 cells [Ghiani & Masini 1995]. In the human 
pancreas ATi-receptor positive cells appear, however, to be distributed to those cells 
stained with insulin [Tahmasebi et al 1999] although the precise localization of the 
AT 1-receptors has not been unequivocally presented. 
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4.3 Regulation of islet RAS components by transplantation 
Islet cell transplantation provides a possibility to accomplish permanent 
normoglycemia in patients with type 1 diabetes mellitus [Kenyou et al 1996]. 
However, its clinical application is severely restricted by the requirement of 
considerable number of islet cells [Ryan et al. 2001; Brendel et al. 2001], which 
might be due, partly, to a lack of proper engraftment thus leading to early graft 
failure [Jansson & Carlsson 2002]. In this regard, a chronically low oxygen tension 
and a markedly decreased blood perfusion have been observed in transplanted islets 
[Carlsson et al 1998，2000，2001]. Interestingly, both chronic hypoxia and 
inflammatory conditions have been shown to activate and upregulate RAS 
components in the pancreas [Chan et al. 2000; Leung et al 2000; Ip et al 2003]. 
In the present study, the expression of AT i-receptors, in contrast to the expression of 
AT2-receptors, ACE and Ao，was found markedly upregulated both at the mRNA and 
protein levels in transplanted islets，as demonstrated by real-time RT-PCR and 
Western blot, respectively (Fig. 3-6 to 3-9，Fig. 3-11). This observation is 
consistent with the enhanced vascular sensitivity to Ang II, when compared to 
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endogenous islets, previously recorded in islet transplants [Olsson et al 2000]. 
As mentioned before, it was observed that exogenous administration of Ang II may 
inhibit glucose-stimulated insulin release in the first phase through vasoconstrictive 
effects [Carlsson et al 1998]. The vasoconstrictive effects of Ang II in transplanted 
islets seemed even more pronounced than in native islets, as also previously observed 
[Olsson et al 2000]. In the present study, Ang II decreased both the first and 
second phase of glucose-stimulated insulin release in transplanted islets [Fig. 3-12 & 
3-13]. Some of the effects of exogenously administered Ang II, especially on the 
second phase, may not merely be related to vascular effects, but direct negative 
effects on (pro)insulin biosynthesis. It is interesting to note that the kinetics of 
glucose-stimulated insulin secretion from the losartan-exposed islet grafts, with its 
distinct first peak, much more mimic that of the perfused mouse pancreas than 
control islet graft without losartan. This may be caused by direct effects of losartan 
on pancreatic |3 cells; however it seems less likely in view of the fact that losartan in 
the present study had no effects on either glucose-stimulated insulin release or 
(pro)insulin and total protein biosynthesis from retrieved islet grafts (Fig. 3-15). 
This implicates that the quantities of endogenously produced Ang II in islet grafts, as 
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in native islets, is not enough to exert negative effects on (pro)insulin biosynthesis. 
This opens the possibility that the low blood perfusion of transplanted islets normally 
restricts and delay the output of insulin to the systemic circulation. The lower 
insulin release in the second phase of losartan-exposed islet transplants would then 
be explained by a "post-washout" effect. Moreover, the improved first phase of 
glucose-stimulated insulin exocytosis may also be due to the higher oxygenation of 
the islet (3 cells. 
The reason for the increased importance of a local RAS in transplanted islets 
compared to endogenous islets is unclear. However, at least in the exocrine 
pancreas inflammatory conditions upregulate several components of the local RAS 
[Leung et al 2000]. High local expression of Ang II may be maintained, or even 
upregulated by chronically low levels of oxygen tension [Chan et al 2000; Ip et al. 
2002], which seem to occur in islet grafts [Carlsson et al 2000]. This hypoxic effect 
on local Ang II formation may at least partially be mediated through increased 
expression of vascular endothelial growth factor [Fujiyama et al. 2001; Saijonmaa et 
al 2001]. 
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4.4 Clinical relevance of islet RAS in transplantation 
One of the crucial importances for the ultimate function of grafted pancreatic islets or 
whole pancreas is the revacularization, reinnervation and blood-flow regulation 
within the transplants. Evidence suggests that the vascular system of transplanted 
islets is different from that of endogenous islets as characterized by a decrease in 
vascular density, blood flow and partial pressure of oxygen. Preliminary 
experiments also suggest that grafted islets have a marked degree of anaerobic 
metabolism, which might hamper a normal regulation of insulin secretion [Jansson 
and Carlsson 2002]. 
Based on the results in the present study, it could be speculated that increased levels 
of Ang II in islet grafts might support islet revascularization, probably via the effect 
of up-regulated ATi receptors. In view of the low oxygenation of grafted islets after 
revascularization, the basal vasoconstriction of high local Ang II levels result in a 
low basal islet graft blood perfusion, and this seems inappropriate in long duration. 
Though with no well know mechanisms, potential use of ATi receptor blocker, 
losartan, can improve graft blood flow and thus insulin secretion, has shed a light 
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into optimal conditions for the survival of transplanted islets in clinical trials. This 
is especially important in view of the shortage of islets which are suitable for 
transplantation. 
4.5 Regulation of islet RAS by Type 2 diabetes 
The function of the pancreatic p cell was studied in relation to the development of the 
diabetic syndrome in a great variety of the diabetic mutant mouse. This was firstly 
produced at The Jackson Laboratory, Bar Harbor, Maine, U.S.A. by outcrossing of a 
C57BLl/KsJ-db stock with C57BL/6J mice. The expression of the db-gene in the 
resulting strain was evaluated by measurements of the body weights and the 
concentrations of serum glucose and serum insulin at different ages of the animals. 
In the diabetic mice the body weight was increased rapidly between 5 and 25 weeks 
of age to a weight twice than the lean controls. During this period, hyperglycaemia 
and hyperinsulinaemia occur with the maximal serum glucose and insulin values 
being observed between 17 and 25 weeks of age. Later on, the serum glucose and 
serum insulin concentrations gradually decrease [Gunnarsson 1975]. This genetic 
model is used as a model to study the development of defects of insulin secretion in 
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T2DM. In previous studies, isolated pancreatic islets from male hyperglycemic 
C57BL/KsJ-db/db mice were used to study (pro)insulin biosynthesis, insulin release 
and insulin content. A diminution of the insulin content to about 36 % and the 
insulin release (20 mmol/l glucose) to nearly one half was observed, whereas 
[3 H] leucine incorporation into (pro)insulin was increased. Insulin biosynthesis as 
well as insulin release showed no further increase, when the glucose concentration 
was increased to 20 or 30 mmol/l [Wilke and Besch 1982]. 
In the presence study, we describe, for the first time, the effect of Ang II and specific 
ATi receptor blocker, losartan on isolated islet insulin release in diabetic (db/db) mice. 
Consistent with previous findings, glucose-stimulated insulin release from db/db 
mice islets is only about one fifth of that of control (m+/db) mice islets. With Ang 
II (100 nmol/l), the glucose-stimulated insulin release could be completely prevented. 
Pretreatment of isolated islets with 1 |imol/l of losartan before the addition of Ang II 
(100 nmol/l) completely restored the insulin secretion to the glucose-stimulated level, 
both in diabetic and control islet. In diabetic islets, addition of losartan significantly 
increased insulin release to a level higher than that with high glucose alone (Fig. 
3-22). 
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As mentioned before, RAS play a pivotal role in regulating islet blood perfusion, 
thereby affecting insulin release by the islet cells [Carlsson et al 1998]. Addition 
of Ang II induced a marked vasoconstriction, which could delay the first phase of 
insulin release in response to glucose. Blockade of the RAS with Ang II antagonist 
Saralasin induced an increase in whole pancreatic blood flow, notably the 
microcirculation of islet blood flow. In the presence study, losartan inhibits the 
vasoconstrictor action of Ang II via the blockade of ATi receptor, thus improving 
intra-islet blood flow and insulin release. 
On the other hand, another possible mechanism for the explanation of the improved 
insulin release by losartan could be due to blockade of amyloid produced in islets of 
diabetic mice. Amyloid deposits are found in pancreatic islets of 90 % of type 2 
diabetic subjects at postmortem. Islet amyloid is formed from islet amyloid 
polypeptide (lAPP) of the |3 cells. lAPP is a 37 amino acid peptide which is a 
normal constituent of p cells and is co-secreted with insulin in animals and in man 
[Ludvik et a/. 1997]. Previous studies have shown that progressive deposition of 
lAPP fibrils combined with the associated reduction in the insulin-secreting p cells is 
likely to contribute to deterioration of islet function in the course of T2DM [Clark et 
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al. 1996 and Wang et al. 1999]. In other words, amyloid act as a local inhibitor of 
stimulated p cells secretion. Evidence has shown that Ang II infusion was 
associated with increased density of amyloid-binding sites whereas, treatment with 
ACE inhibitors reduced blood pressure and the density of amyloid binding in the 
renal cortex [Wookey et al. 1998]. Thus, it can be speculated that locally produced 
amyloid in diabetic mice islet could also be blocked by losartan, thus resulting in 
improved insulin secretion. 
In our study, the local pancreatic RAS components were up-regulated in diabetic 
mouse model, as evidenced from both real-time PGR and immunocytohistochemistry. 
ATi and AT2 receptors, and angiotensinogen were up-regulated by this obesity 
induced diabetes to about 2, 4 and 7 fold, respectively (Fig. 3-16 to Fig. 3-18). In 
contrast, ACE was down-regulated in diabetic mouse pancreas (Fig. 3-19). The 
mechanisms for activation of the islet RAS in the diabetic mice have yet to be 
elucidated. ‘ 
Angiotensinogen, the substrate from which Ang II is formed, was previously shown 
to be elevated in adipose tissue of obese (ob/ob and db/db) mice and regulated by 
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nutritional manipulation such as insulin, glucose, and p-adrenergic agonist. 
Synthesis of Ang II has been described in adipose cells and has been linked to 
regulation of adiposity [Jones et al 1997]. Other component of the RAS has also 
been found in this animal model. ACE and the ACE 2 were measured in kidney and 
heart from 8-week-old nondiabetic control (m+/db) mice and diabetic (db/db) mice. 
Results showed that in young db/db mice, ACE 2 protein in renal cortical tubules is 
increased, whereas ACE protein is decreased. This suggest that the pattern of low 
a c e protein coupled with increased ACE 2 protein expression may be 
renoprotective in early stages of diabetes [Ye et al. 2004]. 
Previous studies also showed that chronic hyperglycemia and hyperlipidemia activate 
the local RAS [Rincon-Choles et al 2002]. Studies of patients with obesity suggest 
that both weight gain and hypertension activate the RAS [Barton et al 2003; Dal 
Ponte et al 1998]. In addition, a recent study demonstrated an increased pancreatic 
expression of RAS components, which is correlated with increased intra-islet fibrosis, 
apoptosis, and oxidative stress in the Zucker diabetic fatty (ZDF) rats [Tikellis. et al. 
2004]. 
It is of great importance that pancreatic islets maintain a specialized architecture for 
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proper function. Disruption of contacts between p cells reduces the secretory 
efficiency of islets. Loss of cell-to-cell communication associated with increased 
islet fibrosis may also promote islet cell apoptosis [Ilieva et al 1999]. 
In the diabetic mice model used for the presence study, islets exhibited a reduced 
proportion of insulin-secreting cells but increased glucagon-, somatostatin, and 
pancreatic polypeptide -containing cells, as compared with islets of control (m+/+db) 
mice [Baetens et al 1978]. The changes in cell populations induced a qualitative 
alteration of cellular interrelationships in the affected islets. Abnormalities in 
ultrastructures of islet capillaries were also detected in db/db mice, as demonstrated 
by the visual inspection and morphometry of electron micrographs. The observed 
changes are: (1) capillary scarcity; (2) increase in the mean and diversity of capillary 
size; (3) pericapillary edema and fibrosis; (4) hypertrophy of the pericyte and 
abundance therein of actin-like microfilaments; and (5) luminal irregularity. 
Changes in (2), (3) and (4) are conceived to indicate hyperperfusion, capillary 
hypertension and secondary vascular response. In particular, such pericyte changes 
were found to be shared by other organs whose capillaries are susceptible to diabetic 
complications [Nakamura et al. 1995]. 
From our immunostaining results, we can see clearly a reduction in insulin producing 
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(3 cell number and a disruption of islet architecture. The RAS has been linked to 
increased fibrosis in various tissues, such as the heart [Seccia et al. 2003], kidney 
[Satoh et al. 2001], and liver [Yoshiji et al. 2001]. It has been recently known that 
locally generated Ang II could upregulated the expression of TGF-p, fibronectin, 
suggesting a role of AT2 receptor in the regulation of fibrogenic action [Leung et al. 
2003] 
Pancreatic islets are highly susceptible to oxidative injury, because of low 
endogenous antioxidant activity [Robertson et al 2003]. Oxidative stress is 
produced under diabetic conditions and is likely involved in progression of 
pancreatic P cell dysfunction as observed in diabetes. Pancreatic p cells are 
vulnerable to oxidative stress probably caused by low levels of antioxidant enzyme 
expressions. In p cells, glucose stimulates the production of reactive oxygen 
species in islet through protein kinase C-dependetn activation of NAD(P)H oxidase 
[Oliveira et al 2003]. Ang II also increases tissue NAD(P)H oxidase activity [Cai 
et al 2002]. ACE inhibitors and angiotensin receptor antagonists were shown to 
indirectly inhibit NAD(P)H oxidase by preventing activation of the ATi receptor 
[Onozato et al 2002]. In the pancreas, recent studies have explored the differential 
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effects of RAS blockers and their potential use in the treatment of pancreatic 
inflammation. Prophylactic administration of saralasin, a non-specific Ang II 
receptor blocker, was shown to improve acute pancreatitis-induced injury in the 
pancreas, while ramiprilat, and ACEI, did not [Tsang et al. 2003]. The protective 
mechanism of saralasin may be linked to alleviation of the increased oxidative stress 
caused by upregulation of Ang II receptors during acute pancreatitis [Ip et al. 2003]. 
In addition, prophylactic and therapeutic administration of ATi receptor (losartan) 
and AT2 receptor (PD123319) antagonists reveals a distinctive action against 
pancreatitis-induced oxidative stress [Tsang et al. 2004]. This beneficial effect may 
be due, in part, to inhibition of the ATi receptor-mediated NADPH 
oxidase-dependent production of free radicals and the impaired pancreatic 
microcirculation seen in acute pancreatitis. 
Taken together, preservation of islet architecture and inhibition of oxidative stress by 
RAS blockade could contribute to the improved insulin fimction. 
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4.6 Clinical relevance of islet RAS in Type 2 diabetes 
Knowledge in diabetes, its treatment and strategies for its prevention make advance 
daily. Treatment is aimed at keeping blood glucose near normal levels at all times. 
Training in self-management is integral to the treatment of diabetes. Treatment must 
be individualized and must address medical, psychosocial, and lifestyle issues 
Treatment options for T2DM mellitus currently consist of diet control, exercise, 
home blood glucose testing, and when dietary treatment and attempts at weight 
reduction of obesity fail to correct hyperglycaemia, oral hypoglycemic agents are 
usually prescribed. Insulin thearapy may be required to achieve satisfactory 
glycemic control even though it is no needed to prevent ketoacidosis in patients with 
T2DM. Approximately 40 % of people with T2DM require insulin injections. 
The major oral medications currently available for treating hyperglycemia in T2DM 
are the class of compounds known as sulfonylureas, e.g. tolbutamide • and 
glibenclamide, which increase the release of endogenous insulin as well as improve 
its peripheral effectiveness. A wider choice of preparations has been available, 
consisting of a second group of compounds, the biguanides, e.g. metformin. These, 
agents reduce blood glucose even in the absence of pancreatic |3 cell function. A 
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third class of drugs are competitive inhibitors of intestinal brush-border, called 
a-glucosidases, which decrease absorption of many carbohydrates from the gut. A 
representative of this class is acarbose. A fourth class of drugs, the 
thiazolidinediones, e.g. troglitazone, act as insulin sensitizers. 
In recent years, ACE inhibitors and angiotensin receptor blockers provide an 
alternative for the treatment of T2DM and its complications 
Diabetes mellitus is an important cause of nephropathy, end-stage renal disease, and 
cardiovascular events. Nephropathy occurs in about 40 % of patients with T2DM. 
It is the leading cause of end stage renal disease (ESRD), and given that treating this 
condition is a considerable economic burden, the prevention of ESRD is a major 
public health goal [Rayner 2004]. Ang II has both haemodynamic and 
non-haemodynamic effects on renal tissue that contribute to the development and 
progression of nephropathy [Williams 2003]. Increased glomerular pressure 
associated with diabetes can be compounded by Ang Il-mediated constriction of the 
glomerular arterioles. This in term causes further elevation in microcirculatory 
pressure within the glomerulus, leading to excretion of albumin, and the development 
of microalbuminuria and proteinuria [Blantz and Gabbai 1987]. In addition to these 
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haemodynamic effects, Ang II can cause further glomerular damage via 
pro-inflammatory effects and pro-fibrotic actions, mediated by factors such as 
transforming growth factor-b (TGF-P). Ang II also has pro-oxidant and 
pro-thrombotic effects that further contribute to renal tissue injury [Jaimes et al. 
1998]. As such, the haemodynamic and non-haemodynamic effects of Ang II 
support the hypothesis that blockade of the Ang II receptor will limit the progression 
of nephropathy. 
Losartan is the first angiotensin receptor blocker to be licensed by the United States 
Food and Drug Administration for the treatment of diabetic nephropathy. The 
current evidence supports the importance of an effective blockade of Ang II receptor 
activity with losartan for renoprotection in patients with diabetic nephropathy. The 
landmark RENAAL (Reduction in Endpoints in Non-Insulin-Dependent Diabetes 
Mellitus with the Ang II Antagonist Losartan) study [Brenner et al 2001] 
demonstrated that losartan conferred renoprotection and reduced, the risk of 
progression to ESRD in patients with T2DM beyond that afforded by conventional 
antihypertensive therapy. The results from Losartan Intervention For Endpoint 
reduction in hypertension study (LIFE) provide additional support for the importance 
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of Ang II in renal disease [Dahlof 2002]. The collective experience with losartan 
suggests that a losartan-based treatment strategy can reduce blood pressure and 
proteinuria in T2DM associated nephropathy. Furthermore, recent research proved 
that losartan reduces urinary albumin excretion in normotensive patients with T2DM. 
In multivariate analysis, the antiproteinuric effect of losartan was independent of the 
associated reduction in blood pressure and was safe and well tolerated in these 
normotensive patients. 
It is well known that T2DM often occurs together with essential hypertension. 
Moreover, hypertension is a risk factor for the subsequent development of T2DM 
[Stem 1995]. It was suggest that some factor(s) common to hypertension and 
diabetes may underlie the strong association between these diseases. Peripheral 
insulin resistance is commonly found in patients with essential hypertension and 
T2DM [Ferrannini et al 1987]. However, it seems that T2DM does not develop as 
long as the pancreatic p cells can secrete sufficient quantities of insulin to maintain 
normal glucose homeostasis [Hellerstrom 1984]. 
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In the Heart Outcomes Prevention Evaluation (HOPE) Study, diabetic patients 
randomized to ramipril had a 24 % risk reduction compared with diabetic patients 
randomized to placebo. These data suggest that ramipril, a tissue-specific ACE 
inhibitor, may provide cardiovascular protection in diabetic patients with associated 
risk factors even in the absence of a prior history of cardiovascular disease or a 
diagnosis of hypertension [Yusuf et al. 2000]. A decreased diabetes incidence after 
treatment with an ACE-inhibitor was also noted in the Captopril Prevention Project 
(CAPP) randomized trial [Hansson et al. 1999]. Furthermore, several studies in 
hypertensive patients receiving long-term treatment with ACE-inhibitors have 
described an increased initial phase insulin peak in response to glucose 
administration [Pollare et al 1989; Hanni et al 1994] or oral glucose [Santoro et al 
1992]. In this regard, early blockade of the RAS may have a clinically significant 
protective effect in subjects with impaired glucose tolerance (IGT)，a category 
between normality and diabetes. Subjects with IGT are indeed at increased risk of 
developing overt diabetes and, even if they do not develop diabetes, atherosclerotic 
vascular disease [Alberti and Zimmet 1998]. On the other hand, The Nateglinide 
And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) 
trial represents a significant milestone in the quest for prevention of T2DM and 
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cardiovascular disease. NAVIGATOR is estimated to determine whether long-term 
administration of nateglinide or valsartan reduce or delay the development of T2DM 
and cardiovascular disease in people with IGT. 
In the present studies with losartan, its beneficial effect in glucose-stimulated insulin 
secretion seems to be mediated via Ang II receptors directly on f> cells in pancreatic 
islets. These results provide a potential mechanism for the beneficial effects of 
RAS inhibition in reducing diabetes incidence in at-risk patients with hypertension 




In conclusion, the current study gives evidence for the presence of an islet 
angiotensin-generating system. This system provides an inhibitory role for locally 
produced Ang II of glucose-stimulated insulin secretion, an effect mediated by the 
ATi receptors located on the surface of the islet (3 cells. The increased expression of 
the ATi receptor in islet transplants and in T2DM could have clinical relevance to 
islet-graft function and T2DM. Application of ATi receptor blocker, losartan, could 
improve insulin secretion in islet graft and in T2DM. On the other hand, perfusion 
experiments on transplanted islet graft shows a markedly improved first phase of 
glucose-stimulated insulin release in transplanted islets when exposed to losartan. 
Inhibition of the local islet RAS maybe, therefore, a feasible strategy to increase the 
function and improve the structure of the islets in islet transplantation and in T2DM. 
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4.8 Further studies 
Although the pancreatic islet RAS and blockade of this system may have clinical 
relevance to islet transplant and T2DM, its underlying mechanisms are still not fully 
understood. Our current results demonstrated the involvement of local RAS in islet 
transplant and T2DM in isolated islets. Regulation of this system and effects of the 
RAS blockers should also be studied in vivo. Further work on the acute 
administration and chronic treatment of losartan, with its addition to the 
post-transplantated and T2DM mice are being undertaken. It will also be intriguing 
to investigate further the role of the islet RAS in islet graft dysfunction, in view of its 
adverse effects on islet graft microcirculation and on the (3 cell mass. To this end, 
the exact mechanism(s) behind the beneficial effects of RAS blockade on islet 
transplantation and on reducing the incidence of T2DM, as observed in large clinical 
trials await further investigations. 
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